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The glioblastoma multiforme (GBM) not only presents the most common tumor of the 
central nervous system in adults, it is also the most aggressive brain tumor. Although 
patients suffering from GBM standardly receive a combination of multiple treatments 
including surgery, radiotherapy and chemotherapy, its prognosis is still poor with a median 
survival time of only 12-15 months. Therefore, new and effective treatment methods are 
urgently needed.  
A signaling molecule which is both involved in proliferation, migration and invasion of a 
broad range of healthy and malignant cells is the lipid mediator sphingosine-1-phosphate 
(S1P). Previous studies have confirmed that sphingosine-1-phosphate (S1P) receptor 1 
(S1PR1) is involved in the regulation of proliferation, invasion, metastasis, vascular 
maturation and angiogenesis of GBM cells, and is closely related to the occurrence and 
development of tumors. Thus, ACT-209905 (provided by Actelion Pharmaceuticals) as a 
selective S1PR1 modulator was applied to gain insights into the molecular processes 
activated by S1PR1 in GBM cells using two human (LN18, U87MG) and one murine (GL261) 
GBM cell line. 
In our in vitro cell viability analyses, we found that ACT-209905 significantly reduced viability 
of LN18 cells in a concentration dependent manner. A combined administration of ACT-
209905 with S1PR2 inhibitors (Compound 16, Compound 16ME – both provided by ONO 
Pharmaceuticals, and JTE-013 – commercially available) showed a stronger effect than the 
single administration demonstrating that both S1PR1 and S1PR2 are involved in growth of 
GBM cells and may interact with each other. Our results also demonstrated that ACT-209905 
can induce apoptosis in GBM cells since caspase 3 activity was induced by the S1PR1 
modulator which might therefore play an important role in inhibiting the proliferation of 
GBM cells. Further, we found a significant inhibitory effect of ACT-209905 on the migration 
and invasion of LN18 and U87MG GBM cells arguing for a participation of S1PR1 signaling in 
migration and invasion of GBM cells, too.  Stimulation of S1P receptors results in the 
activation of several kinases such as AKT1 and ERK1/2, correspondingly our immunoblot 
analyses showed a strong activation of both kinases by S1P which was reduced by ACT-





by S1P in these GBM cell lines. Further studies have to be performed to clarify the role of 
AKT1 and ERK1/2 in the inhibitory effects of ACT-209905 on GBM proliferation, migration 
and invasion. 
Currently, GBM stem cells are discussed as a reason for resistance against the 
radiochemotherapy and the recurrence of the tumor.  Our immunoblot analyses showed 
that Nestin and CD133, two marker proteins for GBM stem cells, were higher expressed in 
GBM cells treated with ACT-209905 compared to control or S1P treated LN18 cells. Further 
investigations in the future might contribute to the elucidation of an involvement of the S1P 
receptors in the stem cell behavior of GBM cells. Paradoxically to the up-regulation of CD133 
and Nestin by ACT-209905, treatment of LN18 stem-like neurospheres with ACT-209905 
showed a significant cytotoxic effect of the compound which was even more pronounced in 
the stem-like neurosphere cells compared to the adherent parental LN18 cells. 
Overall, the studies of this work improve our understanding of the complex mechanisms of 
S1P signaling in GBM cells and might drive the development of its pharmacological 
modulation as a new therapeutic principle in GBM. Furthermore, an extended knowledge 
about the molecular effects of ACT-209905 on GBM cells will broaden the understanding for 
















2.1 Overview of glioblastoma multiforme 
Glioblastoma multiforme (GBM) is the most common malignant tumor of the central 
nervous system in adults, accounting for 35.26% – 60.9% of intracranial tumors [1-3]. It is 
classified by the World Health Organization (WHO) into WHO grade IV by their latest 
intracranial tumor grading standard. GBM represents an astrocytic tumor being highly 
aggressive and invasive to the healthy brain tissue, and thus it can often not be completely 
removed by surgery. The symptoms of GBM depend on the location of the tumor and may 
include persistent headaches, seizures, vision changes, nausea, vomiting, loss of appetite, 
speech difficulties, changes in mood and behavior, energy, cranial nerve defects and motor- 
or paresthesia. The exact cause of GBM development is not clear, and most occur by chance 
without any genetic factors [4]. However, hereditary diseases such as neurofibromatosis and 
tuberous sclerosis are susceptibility diseases which are associated with a higher risk to suffer 
from glioma, and some oncogenes are discussed to be involved in the development of the 
disease [5-11]. 
Glioma mainly spreads in the central nervous system resulting in less distant metastasis. 
Only the bone metastasis of oligodendroglioma is reported in this case [13]. Enhanced 
magnetic resonance imaging (MRI) is a common method for diagnosing gliomas such as GBM 
[14]. 
The current standard therapy of GBM is gross total resection of the contrast enhanced MRI 
parts of the tumor followed by adjuvant radiochemotherapy with temozolomid. However, 
the tumor is often already spread in distant brain areas and is not surgically removable in 
total resulting in a rapid relapse of the tumor [15-19]. Although the treatment of GBM has 
continuously improved in the fields of nursing, surgical resection, radiotherapy and 
chemotherapy, its prognosis has not been substantially improved. The median survival time 
is still only 12 – 15 months [20-22].  By now, treatment methods fail to provide a complete 
cure for glioma, and because of its lack of specificity against target cells toxic side effects can 
cause secondary damage to healthy tissues and organs. Overall, the survival rate of GBM 
patients is not raised significantly after surgery. For example, Tumor-treating fields (TTF) is 





diagnosed GBM and was recently approved by the U.S. Food and Drug Administration (FDA)  
for use in combination with temozolomide [23,24]. The Phase III trial's data show that TTF 
plus chemotherapy after first disease recurrence prolonged overall survival of GBM patients, 
but only for 3 months (11.8 vs 9.2 months) [25]. Therefore, exploring more effective GBM 
comprehensive treatment methods has become a hot topic in medical research. 
 
2.2 Role of Sphingosine-1-Phosphate in tumor biology 
2.2.1 Overview of Sphingosine-1-Phosphate Signaling 
Sphingosine-1-phosphate (S1P) is a bioactive lipid with several important physiological 
functions. It is widely found in body fluids and cells such as blood, lymph, red blood cells, 
neutrophils and platelets [26]. S1P is formed by the metabolism of sphingomyelin by the 
action of sphingomyelinase leading to the formation of ceramide which is which is further 
processed to sphingosine by the enzyme ceramidase. Sphingosine is then phosphorylated by 
the sphingosine kinase (Sphk) isoenzymes 1 and 2 giving rise to S1P [27]. SphK1 is mainly 
present in the cytoplasm, while SphK2 is primarly found in the nucleus [28]. Due to the 
differences in the distribution of SphK isoforms in various tissues and cells, S1P is produced 
in a specific microenvironment and activates its cell surface receptors (sphingosine-1-
phosphate receptors, S1PRs) in an autocrine or paracrine manner. Five different sphingosin-
1-phosphate receptors (S1PR1-5) are known which regulate a variety of biological functions 
such as cell growth, survival, exercise, differentiation, anti-apoptosis, angiogenesis, 
maturation as well as production of cytokines and chemical factors [29, 30]. In addition, S1P 
can also act as a second messenger to act directly within the cell to mediate a variety of 
biological effects [31]. S1P can be dephosphorylated by S1P phosphatases 1 and 2 to form 
sphingosine, or it can be irreversibly decomposed into phosphatidylethanolamine and 
hexadecenal by S1P lyase (S1PL). This maintains the dynamic balance of S1P in the human 
physiological environment [32,33]. 
 
2.2.2 Pathways by which S1P influences tumor growth 
S1P plays an important role in the formation, transformation and progression of various 





Therefore, S1P has been increasingly recognized as an important carcinogen in recent years, 
involving a variety of cancer categories, including breast cancer, colorectal cancer, kidney 
cancer, lung cancer, melanoma, ovarian cancer as well as glioblastoma [35]. The S1P 
receptors (S1PR) seem to be key players in the involvement of progression of these tumor 
types. Interestingly, the intracellular secondary messenger function of S1P and the 
continuously activated signaling pathways are also thought to be a key to regulating cellular 
processes during cancer pathology. Although several studies have revealed the biological 
function of S1P, determining the specific mechanisms involved in a particular cancer type is 
more challenging. This is most likely due to the complex nature of the S1P signaling system, 
cell type-specific effects, abundance or deficiency of specific S1P receptors dependent on 
the cell type, and changes in the intracellular environment [36]. 
S1P can regulate the growth and apoptosis of tumor cells and stimulates angiogenesis, which 
is the result of its biological interaction with different S1PRs. S1PRs belong to the G protein-
coupled receptor family. As mentioned above, five subtypes of S1PRs (1-5) have been found, 
of which S1PR1-3 are ubiquitously expressed in several tissues, while S1PR4 and S1PR5 are 
primarily expressed in blood cells and cells of the central nervous system. Further, all five 
S1PRs (cytoplasmic, and/or nuclear) are widely distributed in benign and/or malignant 
tissues of multiple systems/organs [37]. However, each S1PR subtype is different from the 
others in its systemic distribution, subcellular localization, and difference in the expression 
level between benign and malignant tissues [37]. An overlapping function and an ability of 
some opposite effects are peculiarities of these receptors. However, the role of the 
individual receptor subtype depends on the activation of the respective downstream 
effector proteins, in particular coupling to respective G-proteins [38]. For instance, S1PR1, 
S1PR2 and S1PR5 signal via Gi/o. S1PR2 and S1PR3 activate Gq, and S1PR2, S1PR3, and 
S1PR5 bind with G12/13. These Gα proteins stimulate the Ras/extracellular signal-regulated 
kinase (ERK), phosphoinositide 3-kinase (PI3K)/AKT, and Rho/ Ras homolog gene family 
(RhoA) kinase (ROCK) signaling pathways [39]. In addition, S1PR1 couples via a Gi-protein to 
multiple effector pathways, including phospholipase C (PLC), adenylate cyclase, and 
Ras/MAPK (Ras GTPase/mitogen-activated protein kinase). For example, S1P is known to 
stimulate tumor cell proliferation and migration through binding to S1PR1 whereas S1PR4 





and activate S1PR5 to inhibit the migration of brain glial cells [40-44]. Studies have also 
shown that S1P binds to S1PR1 and S1PR3, which promotes tumor growth and metastasis. In 
contrast, binding of S1P to S1PR2 can inhibit tumor growth and metastasis [45, 46].  
Several studies have confirmed changes in S1P levels, as well as the involvement of their 
receptors and metabolic enzymes in many types of cancer pathophysiology. S1P levels in 
animal models of intestinal tumorigenesis, associated with decreased expression of S1P 
lyase (SPL) and decreased enzyme activity, was seen to increase compared to other local 
tissues [47,48]. In human ovarian cancer patients, S1P is elevated in plasma and malignant 
ascites [49,50]. High expression levels of S1PR1, S1PR3 and the S1P-producing enzyme SphK1 
have also been reported in breast cancer patients [51-55]. Overexpression of SphK1 also has 
been observed in several tumor types of animal and xenograft models compared to 
respective normal tissues, including rat colon adenocarcinoma and mouse leukemia models, 
as well as human breast, lung and colon tumors [56]. Increased proliferation and decreased 
apoptosis are associated with high SphK1 expression in mouse breast cancer cells [57]. S1P, 
the SphK1/2 and the receptors S1PR1-3 and S1PR5 are involved in cell survival and growth, 
and are overexpressed in many tumors including glioblastoma. Elevated levels of S1P were 
found in GBM compared with non-malignant brain tissue. Studies have shown that the 
expression of SphK1 affects the survival of patients with glioblastoma, but the role of 
SphK1/2 and the receptors S1PR1-3 and S1PR5 has not been fully understood in the 
pathogenesis and progression of glioblastoma [58-62].  
2.2.3 S1P signaling in Glioblastoma multiforme 
In the brain, neurons and astrocytes are able to synthesize and release S1P, which is also the 
source of extracellular S1P [63]. In addition, it has been reported in the literature that GBM 
cells can also secrete S1P [64]. Recent studies have shown that S1P has high levels in GBM 
tissues, and S1P is involved in the proliferation, differentiation, survival and migration of 
tumor cells, and can also affect the survival of GBM stem cells [62, 63]. There are also 
reports that indicate high levels of SphK1 expression are closely associated with shorter 
survival times in GBM patients [59,67]. Our in vitro laboratory experiments found that S1P 
can affect the migration and invasion of GBM cells [62], and that S1PR1 and S1PR2 are 





There is no definite evidence to support the involvement of S1P signaling in GBM, but many 
studies have shown that it plays an important role in the regulation of proliferation, invasion 
and migration of GBM cells [reviewed in 68]. Elevated expression levels of S1PR1, S1PR2, 
S1PR3 and S1PR5 can be detected in human GBM tumor tissues [62,69,70]; Further, the 
expression of S1PR1, S1PR2 and S1PR3 was also increased in GBM cells compared with 
healthy brain tissue, but only S1PR1 and S1PR2 were significantly associated with patient 
survival [62,69]. In C6 rat glioma cells, S1PR2 plays a major role for S1P-induced shape 
changes, while S1PR1 and S1PR3 show synergistic effects [71]. However, research from 
Quint and colleagues has shown that S1PR5 is also an important factor affecting the 
prognosis of patients with GBM [72]. 
S1PR1-5 is coupled with Gi/o, and S1PR2 and S1PR3 are coupled with Gq [73]. S1PR1 is not 
but the other S1PRs are coupled with G12/13. When coupled with Gi/o, S1PRs activate 
downstream phospholipase C (PLC), Ras, and Phosphatidylinositol-3-kinase (PI3K). PLC 
regulates cell chemotaxis by activating downstream Ca2+ and protein kinase C (PKC). Ras 
regulates cell proliferation by activating downstream extracellular signal regulated kinase 
(ERK). PI3K affects cell survival and motility by activating downstream protein kinases 
(Proteinkinase B, Akt) and Rac, respectively. When S1PRs are coupled to Gq, the 
downstream PLC can be activated to precipitate the chemotaxis of downstream Ca2+ and PKC 
regulatory cells. When G12/13 is activated by S1PRs, the downstream Rho is activated to 
regulate the anti-migratory performance of the cells [74, 75]. S1PR1 uses Gi proteins to join 
with a variety of effector pathways, including phospholipase C (PLC), adenylate cyclase, and 
Ras/MAPK (Ras GTPase/mitogen-activated protein kinase). In GBM, S1P activates multiple 
signaling pathways in parallel, including mitogen-activated extracellular signal-regulated 
kinase (MAPK/ERK), protein kinase C (PKC), Ca2+ signaling via PLC, and phospholipase D (PLD) 
[76-78]. 
The significant role of S1PR modulators in inhibiting or delaying tumor cell proliferation and 
metastasis has been given more and more attention by researchers, which has opened up 
new ways to approach the treatment of GBM and provided new considerations. Future 
research will reveal if S1P-based treatment options are effective against GBM in patients and 






2.3 S1PR1 and ACT-209905 – an S1PR1 modulator 
S1PR1 was the first S1PR to be discovered and is still the most studied S1PR. S1PR1 is widely 
expressed in tissue cells of various organs and can be found in different parts of the cell, 
such as the nucleus, cytoplasm, cell membrane, and cytoplasm. During embryonic 
development, S1PR1 is highly expressed in the blood vessels and nervous system, which is 
particularly important for the normal development of the vasculature. In adult tissues, 
S1PR1 is highly expressed in the lung, brain and immune organs (such as the marginal zone 
of the spleen) [79]. S1PR1 is biologically diverse and an important lymphocyte surface 
receptor that can effectively promote lymphocyte blood entry [80]. At the same time, S1PR1 
is closely related to various immune system diseases such as autoimmune encephalomyelitis, 
autoimmune diabetes, arthritis and colitis, and participates in affecting many aspects of the 
immune system [81]. 
Current research shows that tumor cells can promote tumor development through S1PR1 
signaling pathways, and increased S1PR1 expression can promote tumor proliferation, 
invasion and metastasis. For example, activation of the S1PR1 promoter can induce the 
expression of endogenous S1PR1 in bladder tumor cells of MB49 mice, thereby promoting 
tumor proliferation and invasion [82]. Furthermore, increasing the expression of S1PR1 in 
renal cell G401 cells and changing the balance of S1PR1/S1PR2 expression causes active 
G401 cells to acquire metastatic properties [83]. Silencing the expression of S1PR1 in tumor 
endothelial cells by small interfering RNA or antagonizing the activity of S1PR1 by antibodies 
can inhibit tumor growth [84]. Liu et al. [85] showed that silencing the S1PR1 gene inhibited 
angiogenesis and neovascularization of transplanted tumors. This study also showed that 
after S1PR1 gene knockout, the maturation and establishment of blood vessels in mice were 
impaired, suggesting that S1PR1 is an important receptor for stimulating tumor angiogenesis 
and vascular maturation. Priceman et al. [86] found that S1PR1 can promote the growth of 
tumors by regulating the enrichment of Treg cells, inhibiting the penetration of CD8+ T cells 
and its function in the B16 mouse model and E0771 medullary breast cancer model, which is 
related to the work of Arikawa et al. [87]. In addition, Chae et al. [88] found that S1PR1 is up-
regulated in tumor blood vessels. Downregulation of its expression can inhibit tumor 





angiogenesis. Further, it was also found that S1PR1 overexpressed in murine melanoma cells 
promoted migration and invasion of cancer cells [87]. 
There is still disagreement about the precise impact of S1PR1 in the pathogenesis and 
progression of GBM. Immunohistochemical analyses from Quint et al. [89] showed that 
S1PR1 is overexpressed in GBM of human patients. However, Watts et al. [90] observed that 
a low expression of S1PR1 in tumor tissue is significantly associated with the worse survival 
rate of patients with malignant glioblastoma. The downregulation of S1PR1 expression 
promoted the proliferation of tumor cells which reduced the survival rate of patients. Our 
team's experimental results also demonstrate that downregulation of S1PR1 expression 
enhances the malignancy of glioblastoma leading to poor survival rates of patients suffering 
from GBM [62] which is in agreement with a study from Yoshida and colleagues [91].  This 
is unexpected since S1P is known to stimulate tumor cell proliferation and migration through 
binding to S1P1. Nevertheless, siRNA-mediated silencing of S1P1 in T98G and G112 glioma 
cells results in increased cell proliferation [91]. Depending on the individual expression of 
S1P1 and the other S1P receptor subtypes as well as the connection to differentially 
activated intracellular signaling pathways, S1P may mediate both pro- and anti-tumorigenic 
effects. Our group could not show an extraordinary role of S1P1 in proliferation of LN18 
glioma cells since the S1P1 inhibitor W146 only slightly decreased cell viability whereas a 
potent function of S1P1 in S1P-mediated GBM cell migration was observed [62]. In general, 
stimulation of cultured GBM cells with S1P either results in unchanged or enhanced cell 
proliferation mediated by S1P1, S1P2 and S1P3 whereas S1P5 inhibits S1P-stimulated cell 
proliferation [92,93]. It has been further shown that motility of GBM cells is stimulated by 
S1P and involves both S1P1 and S1P3 [94]. Our group demonstrated a role of S1P1 and S1P2 
but not of S1P3 in migration of GBM cells [62]. At present, most of the research results 
support the idea that S1PR1 promotes tumor development. Nevertheless, the relationship 
between S1PR1 and GBM needs to be further studied to draw a final conclusion. 
Interestingly, a sphingosine analogue named fingolimod (FTY720), that down regulates 
expression of sphingosine-1-phosphate receptors, causes apoptosis of multiple tumor cell 
types, including glioma cells. This immunosuppressant modulator of S1P signaling, which is 
proved for treatment of multiple sclerosis, also induces apoptosis in brain tumor stem cells 





modulators has been developed by Actelion Pharmaceutics (Basel, Schweiz) such as 
ponesimod (ACT128800) and ACT-209905 [95,96]. The latter one is composed of an amino 
pyridine group, an oxadiazole spacer, a 2-ethyl-5-methylphenol moiety and a chiral 1-amino-
2-propanol side chain (Figure 1).  
 
 
Figure 1. Chemical structure of the S1PR1 modulator ACT-209905 (from [95]). 
 
As FTY720 and ponesimod, ACT-209905 is a S1PR1 receptor modulator with 
immunomodulating properties that could be of use in autoimmune diseases [97,98]. So far, 
there are no reports investigating the potential anti-glioma effects of ponesimod or ACT-
209905.  
Although the signaling mechanisms of S1P receptor subtypes have been comparatively easy 
to recognize, due to their heterogeneity, the S1P signaling pathways involved in the 
pathogenesis of GBM might be quite different. To unravel the complex pathogenic 
mechanisms of GBM, a more in-depth study is required to clarify the role of the S1P signaling 
in the development of GBM. 
 
2.4 Objective 
Glioblastoma (GBM) is the most common malignant tumor of the CNS in the adults. After 
maximal safe surgical resection, the conventional standard of care is radiotherapy with 
concomitant temozolomide followed by maintenance temozolomide [99]. Despite aggressive 
multimodal therapy, the prognosis of patients with GBM is poor [100]. S1P is one of the 
metabolite products of membrane sphingomyelin, and it plays an important role in 
formation, transformation and progression of many malignant tumors as well as the 





receptor subtypes may thus represent a promising therapeutic strategy against the 
progression of GBM.  
Therefore, expression of all five S1P receptor subtypes was also analyzed in different GBM 
cell lines and stem-like GBM cells. Afterwards, the influence of S1P receptor 1 (S1PR1) 
inhibition by ACT-209905 on proliferation, apoptosis and migration were studied in two 
human (LN18, U87MG) and one murine (GL261) GBM cell line. Also, a combined blockade of 
S1PR1 and S1PR2 was investigated in the GBM cells. Further, expression of GBM stem cell 
marker proteins (Nestin and CD133) was analyzed after inhibition of S1PR1 by ACT-209905. 
To gain an insight in the underlying post-receptor signaling pathways, we determined the 
activation status of AKT1 and ERK1/2 as two potential down-stream kinases of the S1PR1. 
Overall, the purpose of this study was to understand the molecular role of S1PR1 in the 
pathognesis of GBM, to pre-clinically evaluate ACT-209905 as possible therapeutic agent in 
GBM cells, and clarify whether ACT-209905 has similar effects as fingolimod on growth 
















3 Material  
3.1 Laboratory equipment and aids   
Cell culture incubator BBD 6220, Heraeus Instruments, Hanau  
Blot Apparatur Biometra®, Göttingen 
Casy® 1 Modell TT  Schärfe-System GmbH, Reutlingen  
ChemiDocTM XRS  Bio-Rad Molecular Imager® Bio-Rad,  
München  
Compact Line OV 4  Biometra®, Göttingen  
Filter paper VWR International GmbH, Hannover  
QBT Dry Block Heating Systems  Bioblock Scientific, Thermolyne Corp.,  
Dubuque, Iowa, USA  
Shaker Rocking Platform, Biometra®, Göttingen  
Infinite M200 Microplate reader TECAN, Crailsheim  
MULTIWELLTM 6/12/96-well-Platten  BD FalconTM, Heidelberg  
Nanodrop ND-1000  peqLab Biotechnology GmbH, Erlangen  
Nitrocellulose membran  Whatman GmbH, Protan®, Dassel  
PIKO Real 96  Thermo Scientific, Waltham, 
Massachusetts, USA  
Pipetboy acu  Integra Biosciences GmbH, Fernwald  
SDS-Page Elektrophoresekammer  Biometra®, Göttingen  
Software  i-Control Infinite M200, TECAN, Crailsheim  
Nanodrop, v3.5.2, Thermo Scientific,  
Waltham, Massachusetts, USA  
Office 2010, Microsoft, USA  
Prism 6 for Windows, v6.01, GraphPad 
Software, Inc., USA  





Standard Power Pack P25  Biometra®, Göttingen  
Laminar flow bench  HERASafe, Heraeus Instruments, Hanau  
T100TM Thermal Cycler  Bio-Rad Laboratories GmbH, München  
Vacuum pump  Vacuubrand, Wertheim  
Vortexer  Reaxtop, Heidolph, Schwabach  
VWR International GmbH, Hannover  
Weighing machine  Explorer, Ohaus, Schweiz  
Water bath  Julabo, Seelbach GFL, Burgwedel  




M-Pact AX822 Balance 
MR 3001 Magnetic Stirring Hotplate 
 
Centrifuge 5430 R Eppendorf AG Hamburg  
Centrifuge 5804 R Eppendorf AG Hamburg 
Heraeus Fresco 21, Thermo Scientific,  
Waltham, Massachusetts, USA  
Sartorius, USA 
Heidolph, Schwabach, Germany 
 
3.2 Chemicals 
Acrylamide  Carl Roth GmbH, Karlsruhe  
AmershamTM ECL SelectTM  
Western Blotting Detection Reagent  
GE Healthcare, Buckinghamshire, UK  
Ammonium persulphate (APS)  Sigma-Aldrich Co, Deisenhofen  
Aprotinin  Sigma-Aldrich Co, Deisenhofen  
Aqua dest.  B. Braun, Melsungen  
Bicinchoninic Acid Solution (BCA)  Sigma-Aldrich Co, Deisenhofen  
Bovine serum albumin (BSA)  Paa Laboratories GmbH, Pasching,  
Ö sterreich  





CAY10444  CAYMAN Chemicals, Michigan, USA  
Desoxyribonucleotidtriphosphate (dNTP)  
(10 mM)  
Applied BiosystemsTM, Weiterstadt  
DMEM Medium  
DPBS Medium 
PAN-Biotech GmbH, Germany 
PAN-Biotech GmbH, Germany 
Ethanol 70 %  Carl Roth GmbH, Karlsruhe  
Fetale calve serum (FCS)  GIBCO®, Invitrogen, Karlsruhe  
Glutamine  GIBCO®, Invitrogen, Karlsruhe  
Glycerol  Carl Roth GmbH, Karlsruhe  
Isopropanol  Carl Roth GmbH, Karlsruhe  
Potassium chloridechlorid (KCl)  Sigma-Aldrich Co, Deisenhofen  
Leupeptin  Sigma-Aldrich Co, Deisenhofen  
Lipofectamine 2000  Invitrogen, life technologiesTM, Darmstadt  
Skimmed milk powder  Krüger GmbH & Co. KG, Bergisch-
Gladbach  
Magnesium chloride (MgCl2) (25 mM)  Promega Corporation, Mannheim  
Methanol  Merck, Darmstadt  
Sodium chloride (NaCl)  Sigma-Aldrich Co, Deisenhofen  
Sodiumdodecylsulfat (SDS)  Carl Roth GmbH, Karlsruhe  
Non-essential Amino acids (NEAS)  Paa Laboratories GmbH, Pasching,  
Ö sterreich  
Penicillin/Streptomycin  Paa Laboratories GmbH, Pasching,  
Ö sterreich  
Phenylmethylsulfonylfluoride (PMSF)  Carl Roth GmbH, Karlsruhe  
Phosphate-buffered saline solution (PBS)  Seromed Biochrom KG, Berlin  
Pierce® BCA Protein Assay  Thermo Scientific, Lumigen Inc., 
Southfield, USA  







Fluorometric Cell Viability Kit I(Resazurin) 
Puromycin dihydrochloride (CAS 58-58-2) 
Actelion Pharmaceuticals, 
Basel,Switzerland 
PromoCell GmbH, Heidelberg, Germany 
Santa Cruz Biotechnology, Inc., USA 
Tetramethylethylendiamine (TEMED)  Carl Roth GmbH, Karlsruhe  
   
Tris-hydrochloride (Tris-HCl)  Carl Roth GmbH, Karlsruhe  
Triton-x-100  SERVA, Heidelberg  
Trypsin / EDTA  PAN-Biotech GmbH, Aidenbach  
W146  Tocris Bioscience, UK 
Caspase-3 Colorimetric Assay 
NeuroCult™ NS-A Basal Medium 
NeuroCult™ NS-A Proliferation Kit 
(Human) 
 
R&D Systems, USA 
Stemcell Technologies Inc., Canada 
Stemcell Technologies Inc., Canada 
3.3 Buffers and solutions 
Blocking Solution 10 %  Skimmed milk powder  
TBST (1 x)  
3 g  
ad 30 ml  




50 ml  
5,5 ml  
5,5 ml  
500 ml  
Laemmli-buffer (4 x)  0,25 mM Tris-HCl (pH 6,8)  
SDS  
Glycerol (100 %)  
Bromophenol blue  
β-Mercaptoethanol  
3.125 ml  
1 g  
5.8 ml  
5 mg  





Aqua dest.  ad 12.5 ml  
Lysis-buffer pH 7.4  50 mM Tris-HCl  
100 mM NaCl  
0.1 % Triton-x-100  
5 mM EDTA  
0.606 g  
0.584 g  
100 μl  
2.5 ml  
Phosphate-buffered  





Aqua dest.  
80.0 g  
2.0 g  
14.4 g  
2.4 g  
ad 1000 ml  
Stacking gel buffer pH 6.8  Tris-HCl  
with NaOH  
Aqua dest.  
6 g  
auf pH 6.8  
ad 100 ml  
Stripping buffer  Tris-Ultra  
SDS  
Aqua dest.  
7.57 g  
20 g  
ad 1000 ml  
Tank  buffer (10 x)  Tris-Ultra  
Glycine  
SDS  
Aqua dest.  
60 g  
288 g  
20 g  
ad 2000 ml  
Tank buffer (1 x)  Tank buffer (10 x)  
Aqua dest.  
100 ml  
ad 1000 ml  
Towbin buffer (10 x)  Tris-Ultra  
Glycine  
Aqua dest.  
60.6 g  
288 g  





Towbin buffer (1 x)  Towbin buffer (10 x)  
Methanol  
Aqua dest.  
100 ml  
200 ml  
ad 1000 ml  
Separating gel buffer pH 8.8  Tris-HCl  
Aqua dest.  
59.1 g  
ad 250 ml  
Washing buffer TBS (10 x)  NaCl  
KCl  
Tris-Ultra  
Aqua dest.  
80 g  
2 g  
30 g  
ad 1000 ml  
pH with HCl to 7.4  
Washing buffer TBST (1 x)  TBS (10 x)  
Tween 20  
Aqua dest.  
200 ml  
800 μl  
ad 2000 ml  
 
3.4 Cell Lines 
In this research, we used three cell lines: two human GBM cell lines (LN18, U87MG) and a 
murine GBM cell line (GL261). The details are as following: 
Name                          Supplier 
LN18                           ATCC, Manassas, VA, USA 
U87MG                         ATCC, Manassas, VA, USA 
GL261                      ATCC, Manassas, VA, USA (kindly provided by M.  
Synowitz, Kiel, Germany) 
 
3.5 Primary and secondary antibodies 
3.5.1 Primary antibodies 
Name Species Molecular Weight Supplier 






Total-Akt1 Rabbit 60 kDa Cell Signaling Technology, Inc., 
Massachusetts 
Phospho-ERK 1/2 Mouse 42/44 kDa Cell Signaling Technology, Inc., 
Massachusetts 
Total-ERK 1/2 Mouse 42/44 kDa Cell Signaling Technology, Inc., 
Massachusetts 
CD133 Mouse  97-120 kDa  Cell Signaling Technology, Inc., 
Massachusetts 
Nestin Mouse 200-250 kDa  STEMCELL Technologies Inc., Canada 
GAPDH Mouse  36 kDa  Meridian Life Science, Inc., USA  
S1PR1 Rabbit 43 kDa Abcam, Oregon, USA 
S1PR2 Mouse 39/48 kDa Santa Cruz Biotechnology, Inc., USA 
S1PR3 Rabbit 42 kDa Abcam, Oregon, USA 
S1PR4 Rabbit 40 kDa Abcam, Oregon, USA 
S1PR5 Rabbit 42 kDa Abcam, Oregon, USA 
 
3.5.2 Secondary antibodies 
Name Species Linked to Supplier 
Anti-mouse goat HRP Bio-Rad Laboratories GmbH, München  






4.1 Cell culture 
The cultivation of the cells was carried out at 37 °C, 95% relative humidity and 5% carbon 
dioxide fumigation in the incubator BBD 6220 (Heraeus Instruments, Hanau). 
Once the GBM cells (LN18, GL261, U87MG) were confluent, they were passaged into a new 
cell culture flask. DPBS, trypsin/EDTA, DMEM (10% FCS, 2mM glutamine and 2mM non-
essential amino acids) were placed in a water bath and preheated to 37 °C before usage. 
For the passage, the medium was aspirated and the cells were washed with 10 ml of pre-
warmed PBS (phosphate buffered saline) twice. The washing process removed serum 
residues and divalent cations (Ca2+, Mg2+). Subsequently, the cells were incubated with 3 ml 
of trypsin/EDTA for three to five minutes in the incubator. Trypsin is a serine protease which 
leads to the detachment of adherently growing cells from the surface of the cell culture flask. 
This process is accelerated by ethylenediaminetetraacetic acid (EDTA), as it complexes 
calcium and magnesium ions and causes the release of cell-cell compounds. The cells were 
detached from the cell culture bottom by gentle tapping, and trypsinization was stopped by 
adding 7 ml of DMEM medium (Dulbecco's Modified Eagle's Medium) with 10% FCS (Fetal 
Calf Serum). 20 ml of DMEM medium containing 10% FCS, 334 μl penicillin/streptomycin and 
0.3 ml of the cell suspension were then pipetted into a new cell culture flask. The 
combination of the antibiotics penicillin and streptomycin prevented contamination with 
Gram-positive and Gram-negative bacteria. 
 
4.2 Determination of the cell number 
The cell number was determined in the CASY TT (Schärfe-System GmbH, Reutlingen). For this 
purpose, 50 μl of the cell suspension was added to 10 ml of isotonic electrolyte solution 
(Casy®ton solution) in a measuring cuvette. The measurement was based on the resistance 
measurement principle. The cell suspension flowed at a constant rate through a capillary 
bearing against a voltage source. When a cell passes the capillary, it displaces some of the 





increase in resistance produces electrical signals whose number is proportional to the cell 
count. 
 
4.3 Cell viability analysis (Resazurine assay and Crystal-violet test) 
GBM cells were inoculated in 96-well plates with 10,000 cells in each well. After 24 hours, 
the medium was removed and the cells were cultured to different time points using fresh 
medium containing S1P or the respective S1P receptor agonist/inhibitor. Then the medium 
was removed and replaced with fresh medium containing 10% resazurine (PromoCell, 
Heidelberg, Germany), and the 96-well plates was returned to the 37 °C cell incubator for 1.5 
to 2 hours, during which the culture medium changed from pure blue to pale pink depending 
on the viability of the cells. The fluorescence readings were recorded using a multi-plate 
reader (Tecan Infinite M200, Crailsheim, Germany, excitation wavelength 530 nm; emission 
wavelength 590 nm). The data was calculated as the percentage of cell viability of solvent 
(MeOH for S1P, DMSO for inhibitors) treated cells. 
Afterwards, the supernatant was aspirated and cells were rinsed once with PBS. Then, cells 
were fixed for 10 minutes with 4 % paraformaldehyde followed by gently rinsing 3 times 
with PBS. 50 μL of 0.5% crystal violet staining solution were added to each well and the 
plates were incubated for 10 min at roomtemperature. Afterwards, the cells were washed 
with A. dest. several times until the dye stops coming off. After washing, the plate was gently 
tapped on filter paper to remove any remaining liquid. Finally, the stained cells were treated 
with 100ul SDS solution (1%) for 5 min while shaking gently on a rocking shaker. The optical 
density of each well was measured at 560 nm (OD560) with a multiplate reader. 
 
4.4 Scratch wound healing assay 
GBM cells were inoculated into a 24-well plate with a total of 150,000 cells per well and a 
volume of 1 ml per well. When the cells have built a complete confluent monolayer, a 
scratch (“wound”) was made with a yellow 100 l pipette tip in the cell layer. Afterwards, 
the culture media was removed and cells were washed twice 1 ml of DPBS to remove the 
isolated cells away to prevent that these cells reattach. DPBS was removed and the pre-





inhibitor. The wounds were imaged using the PALM Robo software of the AxioVision HXP 
120C microscope (Carl Zeiss Microscopy, Jena, Germany), and the exact location of the 
images was saved to analyze the same area after the corresponding incubation time. After 
pre-incubation with hydroxyurea for one hour, the cells were treated with AC-209905 
and/or S1P at different doses for 16 hours in hydroxyurea containing medium, then the 
images were taken again and the wound width was calculated (Software AxioVision SE64 Rel. 
4.9, Carl Zeiss Microscopy). 
 
4.5 Boyden chamber migration assay 
4.5.1 Membrane preparation 
Membranes with a pore diameter of 8 µm were used and coated with collagen (1918 µl A. 
dest., 12 µl 96% Acidic Acid, 70 µl Collagen solution) for 24 hours at room temperature. After 
incubation, the membranes were washed in PBS and hang up to dry. The upper right corner 
(glossy page face up) was cut. Until use, the membrane was covered with a cloth, placed in a 
50 ml tube and put in the fridge (4 °C). 
 
4.5.2 Experimental procedure 
Firstly, GBM cells were seeded cells at a density of 300.000 cells/well in a 6-well-plate as 
usual. 
The migration stimuli for the lower chamber of the Boyden plate were prepared and in each 
well of the lower chamber28 µl were filled in, the membrane (with the glossy page facing up) 
was set on lower chamber and the silicone mat was applied upon the membrane. The upper 
chamber was fixed on it. Then, the cell solution for the upper chamber was prepared: the 
medium was removed from the 6-well-plates and cells were detached by incubation with 
500 µl Trypsin/EDTA for 5 min at 37°C. Next, cells were transferred in 2 mL-Eppis, 500 µL 
medium was added per tube and centrifuged at 1000 rpm for 5 min at 25°C. Now the 
medium was carefully aspirated and cells were resuspended in 1.5 ml medium (with 0.05% 
FCS). Carefully, 50 µl of the cell suspension were filled into each well of the upper chamber. 
The boyden chambers were incubated at 37°C, 95% relative humidity and 5% carbon dioxide 





Afterwards, the membranes were washed in PBS and the cells on the upper side of the 
membrane were scraped. The membranes were washed in PBS again and the cells were 
fixed on the lower side of the membrane in 4% PFA (paraformaldehyde) for 5 minutes. Then, 
the membrane was stained in crystal violet solution for 1 min (crystal violet solution: 5.4 ml 
ethanol [99.8%], 1.5 ml crystal violet). The membrane was washed twice in A. dest. and hang 
up to dry. The following day, the membrane was sticked between a microscopy slide and a 
cover glass with “Entellan®” drying period at least 24 hours). Images of the membrane were 
made using the PalmRobo microscope, and the cells were counted using the software 
“ImageJ”. 
 
4.6 Western blot analysis 
4.6.1 Protein sample preparation 
GBM cells were removed from the incubator, the culture medium was aspirated and 10 ml 
of cold DPBS was added to each flask of cells three times for washing. Then, the cells were 
scraped with cell spatula, transferred to a 1.5 ml centrifuge tube and lysis buffer was added 
(see 3.3 Buffers and Solution). The samples were put on ice for 30 minutes. 
After the completion of the lysis, centrifugation was carried out at 12,000 rpm for 5 min at 
4 °C, and the supernatant resulting from centrifugation was transferred to a new 1.5 ml 
centrifuge tube, and stored at -20 °C. 
 
4.6.2 Preparation of SDS-PAGE gel 
The separation gel (lower layer gel) and the stacking gel (upper layer gel) were prepared 
according to the Table 1 below.  






Aqua dest. 2.1 ml 3.6 ml 3.0 ml 2.4 ml 
Acrylamide 455 μl 1.9 ml 2.5 ml 3.1 ml 
Stacking gel 
buffer 







- 1.9 ml 1.9 ml 1.9 ml 
10% SDS 35 μl 75 µl 75 μl 75 μl 
10% APS 35 μl 75 µl 75 μl 75 μl 
TEMED 3.5 μl 7.5 µl 7.5 μl 7.5 μl 
Table 1. Compositin of the separating gel and the stacking gel (5%). 
 
When all elements of the running chamber are put together, the separation gel is filled in 
and gel is covered with 1-2 ml of isopropyl alcohol to flatten. Gelation is finished after about 
30 min. The ethanol was removed and the stacking gel was overlayed. After 30 to 45 min of 
gelation, the electrophoresis tank solution was filled in the chamber.  
 
4.6.3 Sample Processing 
Before electrophoresis is started, an appropriate amount of 4x SDS-PAGE protein loading 
buffer (4x Laemmli buffer) was added to the protein samples: 30 µl sample and 10 µl loading 
buffer. The samples were heated at 95°C for 5 min before loading 
 
4.6.4 Sample Loading 
The samples were filled into the gel slots with a micropipette. Before adding the next sample, 




In this work the Bio-Rad's standard electrophoresis device was used. The sample was 
electrophoresed with low voltage of 80 V (about 15 minutes) in the stacking gel, and high 
voltage (120 V) was used for electrophoresis in the separating gel. The electrophoresis was 
terminated when the bromophenol blue (from the loading buffer) reaches the bottom end 







The transfer buffer was freshly prepared (see 3.3 Buffers and Solution) and stored at 4°C 
until used. Six sheets of Whatman® filter paper and one nitrocellulose membrane are 
needed for the assembly of the blotting conditions. 
Using Bio-Rad's standard transfer unit, we set the transfer current to 370 mA, transfer time 
to 90 minutes, and ensured the ice box does not overheat. After the transfer was completed, 
Ponceau’s stain liquid was used for five minutes (on a shaker) to check the transfer effect. 
 
4.6.7 Blocking 
The membrane was rinsed three times with TBST washing solution for five minutes each 
time to wash away the Ponceau’s stain solution. Then, 10% skimmed milk blocking solution 
was added, and the membrane was incubated room temperature for 60 minutes on a 
horizontal shaker. 
 
4.6.8 Primary antibody incubation 
After blocking, the membrane was rinsed three times with TBST for five minutes each time. 
The primary antibody diluted to the appropriate concentration (see Table 2 below) with 
















Target protein Molecular weight  Antibody Dilution  
pAkt 1 60 kDa 1 : 1000  
tAkt 1 60 kDa 1 : 1000 
pERK 1/2 42/ 44 kDa 1 : 800 
tERK 1/2 42/ 44 kDa 1 : 800 
CD133  97-120 kDa  1 : 500 
GAPDH  36 kDa 1 : 2000  
Nestin  200-250 kDa 1 : 500  
S1PR1 43 kDa 1 : 1000 
S1PR2 39/48 kDa 1 : 500 
S1PR3 42 kDa 1 : 800 
S1PR4 40 kDa 1 : 1000 
S1PR5 42 kDa 1 : 1000 
Table 2: Summary of Western Blot-Detected Proteins and Primary Antibody Dilutions. 
 
4.6.9 Secondary antibody incubation  
After incubation overnight, the primary antibody solution was removed and the membrane 
was rinsed three times with TBST for five minutes each time. Then, the secondary 
horseradish peroxidase-conjugated antibody (see chapter 3.5.2) was added at a dilution of 
1:1000 and incubated for one hour at room temperature on a horizontal shaker with gentle 
shaking. After incubation, the membrane was rinsed with TBST at room temperature on a 
horizontal shaker three times for five minutes each time. 
 
4.6.10 Detection of proteins 
Chemiluminescence signals were detected with ChemiDoc™ XRS Imaging System (Bio-Rad, 
Hempstead, UK) using ECL Plus Western Blotting Substrate (Thermo Scientific, Rockford, USA) 
followed by densitometric analysis (Quantity One, Bio-Rad). The relative optical densities of 





4.7 Neurosphere culture 
LN18 neurospheres, which are thought to be enriched in cancer stem cells [101], are 
cultured with the NeuroCult™ NS-A Proliferation Kit (Human, STEMCELL Technologies, 
Cologne, Germany) added with 20 ng/ml rh EGF, 10 ng/ml rh bFGF, and 0.0002% heparin 
according to the manufacturer's protocol.  
Briefly, LN18 GBM cells were trypsinized with 3 ml of trypsin/EDTA for 3–5 minutes at 
37°CThen, 7 ml of FCS containing DMEM was added to the flask.  
The cell suspension was transferred to a sterile 15 ml tube and centrifuged at 1000 rpm for 
three minutes. After aspirating the supernatant, the cells were washed with 10 ml of DPBS, 
and the cell suspension was again centrifuged at 1000 rpm for three minutes. This washing 
step with DPBS was repeated twice. Afterwards, the cells were resuspendend into the 
complete NeuroCult™ NS-A Proliferation medium (see above). 
 
4.8 Caspase 3 activity assay 
Caspase 3 activity assay was performed using the commercially available kit Caspase 3 
fluorometric assay (from R&D systems). Cells were seeded in a 96-well plate and incubated 
with respective test substance for appropriate time. After treatment, the medium with cells 
that have been detached due to apoptosis were collected in a conical tube, adherent cells 
were scraped and collected in the same tube. Afterwards, cells were rinsed with ice-cold PBS 
three times and centrifuged at 250 x g for 10 minutes. The supernate was gently removed 
and discarded while the cell pellet was lysed by the addition of the Lysis Buffer. The amount 
of Lysis Buffer to be added to the pellet is determined by the number of cells present. 25 μL 
of cold Lysis Buffer were added per 1 x 106 cells. The cell lysate was incubated on ice for 10 
minutes and then centrifuged at 10,000 x g for 1 minute. The supernatant was tranferred to 
a new tube and kept on ice. After the protein determination assay (BCA Protein Assay), 50 μL 
of cell lysate and 50 μL of 2X Reaction Buffer 3 were mixed. Prior to using the 2X Reaction 
Buffer 3, 10 μL of fresh DTT stock per 1 mL of 2X Reaction Buffer 3 were added. To each 
reaction well (96-well plate) 5 μL of Caspase-3 colorimetric substrate (DEVD-pNA) were 
added and the plate was incubated at 37 °C for 1-2 hours. Then the plates were read on a 






5.1 Expression of S1P receptors in various GBM cell lines 
First, we checked whether S1P receptors are indeed expressed in GBM cells to make sure 
that S1P as well as the S1PR1 modulator ACT-209905 and the S1PR2 inhibitors 
Compound 16/16-ME can act on these cells. To study the expression of S1P receptors in 
GBM cells, five different GBM cell lines derived from humans (A172, GaMG, HF66, LN18 and 
U87MG) and one murine GBM cell line (GL261) were selected. As seen in Figure 2 all S1P 
receptors (1-5) were found on protein level in the investigated human and murine GBM cell 
lines. In the murine GL261 cell line, the S1PR1, S1PR4 and S1PR5 showed a considerably 
lower expression than all human GBM cell lines whereas S1PR2 and S1PR3 seem to have a 
more comparable expression in all tested GBM cells. 
  
Figure 2: Expression of S1P receptors in various GBM cell lines. Five different human GBM cell lines (A172, 
GaMG, HF66, LN18 and U87MG) and one murine GBM cell line (GL261) were analyzed for expression of S1P 








5.2 Influence of ACT-209905 on the viability of GBM cells in vitro  
Treatment of GBM cells with different ACT-209905 concentrations (0.5 to 50 μM) for 24 h, 
48 h and 72 h resulted in significant changes of cell viability (Resazurine assay) and cell 
vitality (Crystal violet staining). 
As shown in Figure 2A-C, in LN18 GBM cells, 10, 20, 30 and 50 μM ACT-209905 significantly 
attenuated the viability after 24 h to 69.2%, 40.3%, 32.1% and 7.3%, respectively (Figure 3A). 
After 48 hours, viability of LN18 cells further decreased to 36.2%, 18.5%, 2.7% and nearly 0% 
(Figure 3B). LN18 cell viability rate decreased to 38.9%, 15.7%, 8.0% and 0.4% after 72 hours 
treatment with 10, 20, 30 or 50 µM ACT-209905 (Figure 3C). Crystal-violet Assay’s results 
(Figure 3D-F) showed that cell vitality decreased to 84.0%, 39.5%, 49.1% and 29.6% after 24 
hours of treatment with 10, 20, 30 and 50 µM ACT-209905 (Figure 3D). The LN18 cell vitality 
after application of 10, 20, 30 or 50 µM ACT-209905 further decreased to 60.7%, 43.7%, 52.3% 
and 31.0% after 48 hours (Figure 3E), and to 41.9%, 33.0%, 39.0% and 24.6% after 72 hours 
treatment, respectively (Figure 3F). Interestingly, for 0.5 and 5 µM ACT-209905 a 
significantly increased cell viability was observed to about 120%. 
     
Figure 3: Treatment of LN18 GBM cells with ACT-209905. The cell viability and vitality of human LN18 GBM 
cells was determined using the resazurine and crystal-violet assay after treatment with ACT-209905 (0.5, 1, 5, 
10, 20, 30 and 50 μM) for 24, 48 and 72 hours. Control cells were treated with MeOH as solvent for ACT-
209905. (A-C) Determination of LN18 cell viability by using the resazurine assay after treatment with ACT-
209905, (D-F) analysis of LN18 cell vitality by using the Crystal-violet assay after treatment with ACT-209905 for 
the respective time points. Cell viability is shown in relation to the MeOH control (100%), mean values and SD, 
n = 5, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and ***p < 





In U87MG cells, treated with 10 to 50 μM ACT-209905, cell viability decreased to 90.7%, 
36.5%, 36.9% and 11.9% after 24 hours (Figure 4A). U87MG cell viability further decreased to 
82.7%, 2.8%, 1.0% and 0.1% after 48 hours of treatment with ACT-209905 (Figure 4B). Cell 
survival rate of ACT-209905 treated U87MG (10, 20, 30 and 50 µM) was diminished to 58.3%, 
13.2%, 1.2% and 0 after 72 hours (Figure 4C). Crystal-violet Assay’s results showed that cell 
vitality of ACT-209905 treated U87MG cells (10, 20, 30 and 50 µM) decreased to 77.4%, 
32.4%, 37.0% and 22.7% after 24 hours (Figure 4D). U87MG cell vitality was further 
significantly reduced to 33.1%, 29.2% and 26.5% 48 hours after application of 20, 30 or 
50 µM ACT-209905, and to 70.7%, 30.3%, 23.0% and 21.2% after 72 hours treatment with 10, 
20, 30 or 50 µM ACT-209905, respectively (Figure 4F). 
 
  
Figure 4: Treatment of U87MG GBM cells with ACT-209905. The cell viability and vitality of human U87MG 
GBM cells was determined using the resazurine and crystal-violet assay after treatment with ACT-209905 (0.5, 
1, 5, 10, 20, 30 and 50 μM) for 24, 48 and 72 hours. Control cells were treated with MeOH as solvent for ACT-
209905. (A-C) Determination of LN18 cell viability by using the resazurine assay after treatment with ACT-
209905, (D-F) analysis of LN18 cell vitality by using the Crystal-violet assay after treatment with ACT-209905 for 
the respective time points. Cell viability is shown in relation to the MeOH control (100%), mean values and SD, 
n = 5, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and ***p < 
0.001 vs. MeOH control. 
 
In the murine GL261 GBM cells, 20 to 50 μM ACT-209905, viability also decreased to 61.7%, 
42.7% and 18.4% after 24 hours (Figure 5A). Cell viability decreased to 8.9%, 23.6% and 0% 
after 48 hours of treatment of GL261 cells with 20, 30 or 50 µM ACT-209905 (Figure 5B). And, 





with 20, 30 and 50 µM ACT-209905 (Figure 5C). The results of crystal-violet Assay showed 
that cell vitality was siginificantly decreased to 51.4%, 51.9% and 27.0% after 24 hours of 
treatment of GL261 cells with 20, 30 or 50 µM ACT-209905 (Figure 5D). 48 hours after 
application of 20, 30 and 50 µM ACT-209905, cell vitality was significantly reduced to 59.2%, 
38.6% and 21.1% (Figure 5E). Cell vitality was significantly diminished to 36.9%, 34.2% and 
31.2% after 72 hours of treatment with 20, 30 or 30 µM ACT-209905, respectively (Figure 5F). 
 
Figure 5: Treatment of GL261 GBM cells with ACT-209905. The cell viability and vitality of murine GL261 GBM 
cells was determined using the resazurine and crystal-violet assay after treatment with ACT-209905 (0.5, 1, 5, 
10, 20, 30 and 50 μM) for 24, 48 and 72 hours. Control cells were treated with MeOH as solvent for ACT-
209905. (A-C) Determination of LN18 cell viability by using the resazurine assay after treatment with ACT-
209905, (D-F) analysis of LN18 cell vitality by using the Crystal-violet assay after treatment with ACT-209905 for 
the respective time points. Cell viability is shown in relation to the MeOH control (100%), mean values and SD, 
n = 5, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and ***p < 
0.001 vs. MeOH control.  
 
5.3 Influence of ACT-209905 and S1P on the migration of LN18 and GL261 GBM cells  
Further, the influence of ACT-209905 on GBM cell migration was investigated. Migration of 
LN18 and GL261 cells was analysed with the scratch wound healing assay (after 16 h) and the 
Boyden chamber assay (after 3 h). Selected examples of both assays are illustrated in Figure 
6A and 7A, whereas the statistical analyses are shown in Figure 6B and 7B. In LN18 GBM cells, 
10 μM and 30 μM ACT-209905 treatment reduced the migration significantly to 82.4% and 
59.7% (Figure 6). The motility of GL261 cells treated with 10 μM and 30 μM ACT-209905 was 





The additional application of S1P reversed the inhibitory effect of ACT-209905 on migration 























































Figure 6: Influence of ACT-209905 on migration of LN18 GBM cells. LN18 cell migration was analyzed using the 
wound closure assay by scratching the cell layer and adding the ACT-209905 (ACT, 1 μM, 10 μM, 30 μM), then 
measuring the wound width at the beginning of the experiment (0 h) and again after 16 hours with S1P (2.5μM). 
Cell proliferation was inhibited by co-application of hydroxyurea (5 mM). (A) Illustration of representative 
images of LN18 cells at 0 and 16 hours, (B) statistical analysis of LN18 GBM cell migration behaviour. Wound 
closure ability is shown in relation to the MeOH control (Con, 100%), mean values and SD, n = 3, one-way 



























































Figure 7: Influence of ACT-209905 on migration of GL261 GBM cells. GL261 cell migration was analyzed using 
the wound closure assay by scratching the cell layer and adding the ACT-209905 (ACT, 1 μM, 10 μM, 30 μM), 
then measuring the wound width at the beginning of the experiment (0 h) and again after 16 hours with S1P 
(2.5μM). Cell proliferation was inhibited by co-application of hydroxyurea (5 mM). (A) Illustration of 
representative images of LN18 cells at 0 and 16 hours, (B) statistical analysis of LN18 GBM cell migration 
behaviour. Wound closure ability is shown in relation to the MeOH control (Con, 100%), mean values and SD, n 
= 3, one-way analysis of variance with Dunnett ś multiple comparison test, **p < 0.005 and ***p < 0.0001 vs. 
control. 
 
To further analyze the effect of ACT-209905 on GBM cell migration, we used the Boyden 





results are shown in Figure 8. The migration of LN18 GBM cells was significantly lesser in the 
10 μM and 30 μM ACT-209905 treatment groups. In comparison to the MeOH treated 
control cells, which were set to 100% migratory potential, the relative number of migrated 
cells was significantly reduced to 88.8% and 84.2% 6 hours after application of 10 and 30 µM 
ACT-209905, while the relative number of migrated cells in the S1P co-treated group was 
98.9% and 90.6%. The single application of LN18 cells with 2.5 µM S1P resulted in enhanced 
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Figure 8: Analysis of LN18 cell migration using the Boyden chamber assay. Cells were allowed to migrate for 
three hours after application of S1P (2.5 μM) alone or together with ACT-209905 (ACT, 10 μM), fixed on the 
lower side of the membrane, stained with crystal violet, and then counted. Representative images of the 
migrated and stained cells are shown in the upper panel of the figure. Counted cells (lower panel) are shown in 
relation to the control (con, 100%), mean values and SD, n = 3, one-way analysis of variance with Dunnett ś 






5.4 Influence of ACT-209905 on AKT1 and ERK1/2 activation 
Immunoblotting was used to analyze the influence of ACT-209905 on the phosphorylation 
and activation status of AKT1 and ERK1/2 (normalized to the total kinase) to determine 
whether these kinases might be involved in the inhibitory effect of ACT-209905 on GBM cell 
viability and migration. Firstly, the phosphorylation of AKT1 (pAKT1) and ERK1/2 (pERK1/2) 
was investigated 5, 10 and 30 minutes after stimulation of LN18 cells with 2.5 μM S1P. 
Results of the LN18 GBM cells are illustrated in Figure 9. In the S1P-treated group, the 
phosphorylation state was significantly increased by a factor of 2.5 after 5 minutes (Figure 
9C and 9D). The elevated pAKT1 status was also seen after 10 and 30 minutes of S1P 
treatment but this was not so pronounced. In contrast, in LN18 cells pre-treated for 24 hours 
with 10 µM ACT-209905, a significant increase in pAKT1 was not observed in the S1P-treated 
group. The phosphorylation of ERK1/2 (pERK1/2) was also significantly elevated after 5, 10 






















































































































































































































































































   
Figure 9: Immunoblot analysis of phosphorylated (p) and total (t) AKT1 and ERK1/2 in LN18 GBM cells. LN18 
cells were treated with 2.5 μM S1P for 5, 10 and 30 min as well as 1 h and 3 h. Further, in the 
combined treatment group, firstly 10 μM ACT-209905 (ACT) was added for 24 h and afterwards the cells were 
treated with 2.5 μM S1P for 5 min, 10 min, 30 min, 1 h and 3 h. (A and C) Immunoblot analysis of AKT1 and (B 
and D) immunoblot analysis of ERK1/2. Representative blots are shown in the panels (A) for AKT1 and (B) for 
ERK1/2. The corresponding densitometric analyses are shown in the panels (C) for AKT1 and (D) for ERK1/2, the 
phosphorylated protein level (p) was normalized to the total protein level (t), mean values and SD, n = 5, One-








This S1P-induced increase in pERK1/2 was slightly reduced by pre-treatment of LN18 cells 
with ACT-209905 for 24 hours but there was still a significant pERK1/2 increase in the S1P-




In the murine GL261 GBM cells (Figure 10), the single application of S1P did not result in an 
elevated pAKT1 status. But interestingly, the combined stimulation of GL261 cells with 10 
µM ACT-209905 (pre-treated for 24 hours) and 2.5 µM S1P caused a significant elevation in 
pAKT1 after 5 and 30 minutes and after 1 and 3 hours. ACT-209905 alone was not able to 
increase the pAKT1 status (Figure 10A and C). In contrast, the phosphorylation status of 
ERK1/2 (pERK1/2) was significantly enhanced after 5, 10 and 30 minutes of S1P treatment. 
Interestingly, the combined application of ACT-209905 (pre-treated for 24 hours) and S1P 
resulted in a three times stronger up-regulation of pERK1/2 after 5 minutes than the single 
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Figure 10: Immunoblot analysis of phosphorylated (p) and total (t) AKT1 and ERK1/2 in GL261 GBM cells. 
GL261 cells were treated with 2.5 μM S1P for 5, 10 and 30 min as well as 1 h and 3 h. Further, in the 
combined treatment group, firstly 10 μM ACT-209905 (ACT) was added for 24 h and afterwards the cells were 
treated with 2.5 μM S1P for 5 min, 10 min, 30 min, 1 h and 3 h. (A and C) Immunoblot analysis of AKT1 and (B 
and D) immunoblot analysis of ERK1/2. Representative blots are shown in the panels (A) for AKT1 and (B) for 
ERK1/2. The corresponding densitometric analyses are shown in the panels (C) for AKT1 and (D) for ERK1/2, the 
phosphorylated protein level (p) was normalized to the total protein level (t), mean values and SD, n = 5, One-






5.5Influence of ACT-209905, Compound 16 and Compound 16-ME on CD133 and Nestin 
protein expression  
It is postulated that a tumor contains a subpopulation of tumor cells that exhibit key defining 
characteristics of somatic stem cells, including the ability to exhibit self-renewal, multipotent 
differentiation and the expression of stem cell markers such as CD133 and Nestin [102-105]. 
To investigate whether inhibition of S1PR1 or S1PR2 signaling is involved in regulation of 
stem cell behavior, LN18 and GL261 GBM cells were treated with S1P,  ACT-209905 (S1PR1 
antagonist), Compound 16 (antagonist of S1PR2), Compound 16-ME (antagonist of S1PR2) 
and analyzed the protein expression of CD133 and Nestin by immunoblotting. The respective 
















































































































































































Figure 11: Immunoblot analysis of the stem cell marker CD133 and Nestin. LN18 GBM cells were treated with 
10 μM ACT-209905 (ACT), 2.5 μM S1P, 10 μM Compound 16 (Comp 16) or Compound 16-ME (Comp 16-ME) for 
6 h. For the combined treatment of the substances, LN18 cells were pre-treated with 10 μM ACT-209905 for 24 
h and 10 μM Comp 16/Comp 16-ME for 6 h followed by application of 2.5 μM S1P for 6 h. Control cells were 
treated with MeOH. Treated cells are shown in relation to the MeOH control (100%), mean values and SD, n = 3, 







In LN18 cells, treatment ACT-209905 alone and in combination with Compound 16, 
Compound 16-ME and S1P resulted in a significantly elevated CD133 protein expression of 
about 150% compared to the MeOH control cells. In contrast, Nestin protein expression was 
only significantly enhanced by single application of ACT-209905 (Figure 11A and C). 
In murine GL261 cells, the results for CD133 and Nestin protein expression differ from those 
of human LN18 GBM cells as illustrated in Figure 12. Treatment of GL261 cells with ACT-
209905 did not result in a change of CD133 or Nestin protein expression. In contrast, single 
application of S1P and Compound 16-ME caused a significant up-regulation of both CD133 
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Figure 12: Immunoblot analysis of the stem cell marker CD133 and Nestin. GL261 GBM cells were treated with 
10 μM ACT-209905 (ACT), 2.5 μM S1P, 10 μM Compound 16 (Comp 16) or Compound 16-ME (Comp 16-ME) for 
6 h. For the combined treatment of the substances, LN18 cells were pre-treated with 10 μM ACT-209905 for 24 
h and 10 μM Comp 16/Comp 16-ME for 6 h followed by application of 2.5 μM S1P for 6 h. Control cells were 
treated with MeOH. Treated cells are shown in relation to the MeOH control (100%), mean values and SD, n = 3, 







To further validate the molecular mechanisms of ACT-209905 and Compound 16/16-ME 
regarding GBM stem cell behavior, we pre-treated human LN18 and murine GL261 GBM cells 
with ACT-209905, Compound 16 or Compound 16-ME for 24 hours followed by application 
of S1P for 6 or 24 hours. Afterwards, the expression of the stem cell marker CD133 and 
Nestin was analyzed by immunoblotting. As seen in Figure 12 in the LN18 GBM cell line, 
there was a significant increase in the expression of CD133 after treatment with all tested 
drugs for 6 hours (Figure 13A). The strongest effect was observed for treatment with ACT-
209905 alone (399.2%) which was similar to the combined application of ACT-209905 and 
S1P (369.3%). Compound 16 and Compound 16-ME increased the expression of CD133 to 
344.8% and 258.5%, respectively, and this effect was somewhat smaller when the 
compounds were combined with S1P (293.0% and 185.3%). The single application of S1P 
caused an increase of CD133 protein expression to 294.4% in LN18 cells after 6 hours (Figure 
13A). After 24 hours, the rise in CD133 expression was not so pronounced as seen for the 6 
hours incubation time. Here, the single application of ACT-209905 and Compound 16 did not 
result in an elevated CD133 protein expression whereas Compound 16-ME caused an 
increase to 237.9%. The application of S1P alone as well as the combination with ACT-
209905 or Compound 16-ME, but not with Compound 16, also enhanced the CD133 protein 
expression to 216.4%, 241.6% and 364.2%, respectively.  
Nestin protein expression was significantly elevated in LN18 cells after 6 hours by single 
application of S1P, ACT-209905 and Compound 16 to 226.3%, 261.4% and 197.8%, 
respectively (Figure 13B). Also, the combination of S1P with ACT-209905 increased the 
Nestin expression (255.3%) in similar way as for the single ACT-209905 treatment. These 
inducing effects were strongly mitigated after 24 hours of treatment. 
In contrast, in GL261 GBM cells, only the combined application of ACT-209905 and S1P 
caused a significant increase in CD133 expression to 170.6% and 136.6% after 6 and 24 hours  
(Figure 13C). An enhanced Nestin protein expression in GL261 cells was seen for all tested 
substances after 6 hours whereby the strongest induction was caused by the combined 
application of ACT-209905 and S1P to 285.6% (Figure 13D) which was much higher than for 
single treatment with S1P (217.0%) or ACT-209905 (176.3%) (Figure 13D). The changes in 
Nestin protein expression in GL261 cells after 24 hours were consistent with the results from 





Nestin protein expression in GL261 cells was found for combined treatment with ACT-
209905 and S1P. 
 
 
Figure 13: Immunoblot analysis of CD133 and Nestin protein expression in the LN18 and GL261 GBM cell lines. 
After 24 hours of pre-treatment with ACT-209905 (ACT, 10 μM), Compound 16 (Comp 16, 10 μM) and 
Compound 16-ME (Comp 16-ME, 10 μM), 2.5 µM S1P was given for 6 hours and 24 hours. Afterwards, the 
extracted proteins were subjected to immunoblot analysis. Control cells were treated with MeOH (0.1%). (A+B) 
Expression of CD133 and Nestin in human LN18 GBM cells, (C+D) expression of CD133 and Nestin in murine 
GL261 GBM cells. Treated cells are shown in relation to the MeOH control (set to 100%), mean values and SD, n 
= 3, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and ***p < 






5.6 Effect of a dual inhibition of S1PR1 and S1PR2 signaling by different compounds on 
viability of GBM cells in vitro 
To understand the role of the S1P signaling pathways on GBM cell growth, different 
inhibitors of S1PR1 and S1PR2 were used: ACT-209905 (S1PR1 modulator/antagonist), 
Compound 16/16-ME (S1PR2 antagonists), JTE-013 (S1PR2 antagonist) and W146 (S1PR1 
antagonist). Figures 13-15 show the results of single treatment or a combination of the 
respective substances on viability of the human LN18 and U87MG GBM cells as well as the 
murine GL261 GBM cells. 
In LN18 GBM cells (Figure 14A-D), Compound 16, W146 and JTE-013 treatment as well as the 
combined application of Compound 16 and W146 decreased the cell viability to 65.7%, 
71.2%, 64.9%, 76.0% and 70.6% after 6 hours. After 24 hours, the single application of 
Compound 16 and JTE-013 resulted in a significantly reduced viability of LN18 cells. 
Additionally, all combined treatment regimens decreased the viability of LN18 cells 
significantly with the exception of the dual application of Compound 16-ME and W146. The 
cell viability further decreased significantly after 48 and 72 hours of treatment as seen in 
Figure 12C and D. The strongest effects were observed after 72 hours for the combined 
application of the Comp 16-ME/ACT-209905 and JTE-013/ACT-209905 and JTE-013 (7.6% and 
13.7%). Similar results were found for the determination of LN18 cell vitality using crystal 
violet staining (Figure 14E-H). 
In human U87MG GBM cells (Figure 15B), after 24 hours of treatment with JTE-013 alone as 
well as all dual S1PR1/2 blocking regimens caused a significantly reduced cell viability 
whereas after 6 hours only the single application of JTE-013 was associated with a decreased 
U87MG viability (Figure 15A). After 48 hours, the single application of ACT-209905, 
Compound 16 and JTE-013 decreased the viability of U87MG cells significantly. Except for 
the combined application of Compound 16-ME and W146, the cell viability upon all other 
dual S1PR1/S1PR2 blocking regimens was significantly reduced. After 72 hours, with the 
exception of the single application of W146, all other single and dual blocking regimens using 
ACT-209905, Compound 16, Compound 16-ME, JTE-013 and W146 resulted in a significant 
reduction of the cell viability of U87MG cells (Figure 15D). Again, the results of the cell 
vitality analyses with crystal violet staining showed similar results as the cell viability 
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Figure 14: Treatment of LN18 GBM cells with ACT-209905, Compound 16, Compound 16-ME, JTE-013 and 
W146. Resazurine assay (A-D) and Crystal-violet assay (E-H) after treatment with ACT-209905 (ACT, 10 μM), 
Compound 16 (Comp 16, 10 μM), Compound 16-ME (Comp 16-ME, 10 μM), JTE-013 (10 μM) and W146 (10 μM) 
for 6, 24, 48 and 72 h, administered alone and in combination. Control cells were treated with MeOH (0.1%). 
Cell viability (Resazurine assay) and cell vitality (Crystal-violet assay) are shown in relation to the MeOH control 
(set to 100%), mean values and SD, n = 4, one-way analysis of variance with Dunnett ś multiple comparison test, 
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Figure 15: Treatment of U87MG GBM cells with ACT-209905, Compound 16, Compound 16-ME, JTE-013 and 
W146. Resazurine assay (A-D) and Crystal-violet assay (E-H) after treatment with ACT-209905 (ACT, 10 μM), 
Compound 16 (Comp 16, 10 μM), Compound 16-ME (Comp 16-ME, 10 μM), JTE-013 (10 μM) and W146 (10 μM) 
for 6, 24, 48 and 72 h, administered alone and in combination. Control cells were treated with MeOH (0.1%). 
Cell viability (Resazurine assay) and cell vitality (Crystal-violet assay) are shown in relation to the MeOH control 
(set to 100%), mean values and SD, n = 4, one-way analysis of variance with Dunnett ś multiple comparison test, 
*p < 0.05, **p < 0.005 and ***p < 0.001 vs. control. 
 
In murine GL261 GBM cells (Figure 16A), after 6 hours, with the exception of the dual 
application of Compound 16-ME and W146, all other single and dual S1PR1/S1PR2 blocking 
regimens  decreased the viability of GL261 cells significantly. After 24 hours of treatment, 
the GL261 cell viability was significantly reduced in all single and dual application protocols 
except for the single application of Compound 16 and the combined treatment with 
Compound 16-ME and W146. After 48 hours, Compound 16, Compound 16-ME and JET-013 
treatment caused a significant reduction of GL261 cell viability. Additionally, the 
combination of ACT-209905 with Compound 16 or JTE-013  also resulted in significantly 





groups was significantly reduced with the strongest effects seen for dual application of ACT-
209905 together with Compound 16-ME or JTE-013. For GL261 cell vitality using crystal 
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Figure 16: Treatment of GL261 GBM cells with ACT-209905, Compound 16, Compound 16-ME, JTE-013 and 
W146. Resazurine assay (A-D) and Crystal-violet assay (E-H) after treatment with ACT-209905 (ACT, 10 μM), 
Compound 16 (Comp 16, 10 μM), Compound 16-ME (Comp 16-ME, 10 μM), JTE-013 (10 μM) and W146 (10 μM) 
for 6, 24, 48 and 72 h, administered alone and in combination. Control cells were treated with MeOH (0.1%). 
Cell viability (Resazurine assay) and cell vitality (Crystal-violet assay) are shown in relation to the MeOH control 
(set to 100%), mean values and SD, n = 4, one-way analysis of variance with Dunnett ś multiple comparison test, 












5.7 Expression of S1P receptors in LN18 GBM stem-like neurospheres 
Immunoblotting was used to compare and evaluate the expression of S1P receptors in 
adherent LN18 cells and stem-like LN18 neurospheres. For this purpose, LN18 cells were 
cultured in serum-free medium in the presence of growth factors (EGF, bFGF, heparin) with 
formation of neurospheres bearing stem cell features [106-108]. As control, LN18 cells are 
maintained in parallel as adherent cells under standard conditions in serum containing 
medium (10% FCS). The results of the immunoblot analysis are shown in Figure 17 
demonstrating that the expression of S1PR1, 2, 3 and 5 is slightly higher in stem-like LN18 
neurospheres than in adherent LN18 GBM cells. This increase was only statistically 
significant for the expression of S1PR2. 
     
 
Figure 17: Expression of S1P receptors in LN18 GBM stem-like neurospheres. LN18 GBM cells were cultured 
for 4 and 7 days either as adherent cells in serum-containing standard medium (10% FCS) and as stem-like 
neurospheres in serum-free medium in the presence of EGF, bFGF and heparin. Afterwards, proteins were 
separately extracted for subsequent Western blotting experiments. (A) S1PR1 expression, (B) S1PR2 expression, 
(C) S1PR3 expression and (D) S1PR5 expression. S1P receptor expression of LN18 neurospheres is shown in 
relation to the adherent LN18 cells (set to 100%), mean values and SD, n = 3, one-way analysis of variance with 





5.8 Viability of GBM cells after treatment with ACT-209905, Compound 16 and 
Compound 16-ME together with temozolomide (TMZ) in vitro 
The current standard chemotherapeutic drug for clinical treatment of GBM is temozolomide 
(TMZ). In this set of experiments, we investigated whether an inhibition of S1PR1 (by ACT-
209905) or S1PR2 (by Compound 16 and Compound 16-ME) sensitizes GBM cells against 
TMZ. As seen in Figure 16, we did not find a significant synergistic or additive effect between 
ACT-209905 and TMZ in GBM cells. We unexpectedly found that that in some cases TMZ 
appeared to reverse the cytotoxic effects of ACT-209905 in the murine GL261 GBM cell line 
















Figure 18: Influence of ACT-209905 and TMZ on cell viability of GBM cells. Resazurine assay (A, C, E) and 
Crystal-violet assay (B, D, F) after treatment of GBM cells with ACT-209905 (ACT, 1 µM, 5 µM, 20 µM, 50 µM), 
Temozolomide (TMZ, 100 μM) for 24 hours, administered alone and in combination. Control cells (CON) were 
treated with MeOH. (A) LN18 cell viability using the resazurine assay. (B) LN18 cell vitality using the Crystal-
violet assay. (C) U-87MG cell viability using the resazurine assay. (D) U-87MG cell vitality using the Crystal-violet 
assay. (E) GL261 cell viability using the resazurine assay. (F) GL261 cell vitality using the Crystal-violet assay. Cell 
viability and cell vitality are shown in relation to the control (set to 100%), mean values and SD, n = 3, one-way 
analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and ***p < 0.001 vs. 
control. 
 
Furthermore, we treated the GBM cells with Compound 16 and Compound 16-ME together 
with TMZ in comparison to the single application of ACT-209905, Copmpound 16 and 
Compound 16-ME. The results of the respective cell viability/vitality analyses are shown in 
the Figure 18-20 below. 
In the human GBM cell lines LN18 (Figure 19) and U87MG (Figure 20), the viability of all cells 
treated for 48 and 72 hours with ACT-209905 alone or in combination with Compound 16, 
Compound 16-ME and TMZ was strongly reduced which was more pronounced in the 





to reverse the cytotoxic effects of ACT-209905 in GL261 cells (Figure 20), but this was not 
observed in the human GBM cells. 
In LN18 cells, ACT-209905 alone reduced the viability to 73.9%, this effect was more 
pronounced in the ACT-209905/Compound 16 treatment group (21.2%), in the ACT-
209905/Compound 16-ME treatment group (nearly 0%), ACT-209905 and together with TMZ 
(17.8%) after 48 hours (Figure 18A). The combination of Compound 16 or Compound 16-ME 
as inhibitors of S1PR2 with TMZ did not result in a signifcantly decreased cell viability. 
Interestingly, the combination of ACT-209905 with TMZ showed nearly similar effects as the 
combination of ACT-209905 with Compound 16. Very similar effects were seen after 72 
hours of treatment (Figure 19B). The results of the LN18 cell vitality analyses are seen in 
Figure 18C+D showing the same as the cell viability data. 
In the U87MG cells, the application of 10 µM ACT-209905 alone caused no significant 
decrease of the cell viability after 48 and 72 hours. The dual application of ACT-209905 with 
Compound 16 or Compound 16-ME showed the strongest cytotoxic effects both after 48 
hours (45.8% and 39.2% cell viability, Figure 20A) and 72 hours (24.0% and 23.0% cell 
viability, Figure 20B), too. The combination of Compound 16 or Compound 16-ME, as 
inhibitors of S1PR2, with TMZ also significantly reduced the U87MG to 71.2% and 62.2% 
after 48 hours, and to 52.2% and 44.8% after 72 hours, respectively (Figure 20A+B). This 
effect was just as strongly as for the combination of ACT-209905 with TMZ whereas the 
single application of 10 µM ACT-209905 caused no significant decrease of U87MG cell 
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Figure 19: LN18 GBM cell viability and vitality after dual treatment with ACT-209905, Compound 16, 
Compound 16-ME and temozolomide. Resazurine assay (A+B) and Crystal-violet assay (C+D) after treatment 
with ACT-209905 (ACT, 10 µM), Compound 16 (Comp 16, 10 µM), Compound 16-ME (Comp 16-ME, 10 µM) and 
temozolomide (TMZ, 100 μM) for 48 and 72 h, administered alone and in combination. Control cells (CON) 
were treated with MeOH. (A+B) LN18 cell viability using the resazurine assay. (C+D) LN18 cell vitality using the 
Crystal-violet assay. Cell viability and vitality are shown in relation to the control (set to 100%), mean values 
and SD, n = 3, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and 
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Figure 20: U87MG GBM cell viability and vitality after dual treatment with ACT-209905, Compound 16, 
Compound 16-ME and temozolomide. Resazurine assay (A+B) and Crystal-violet assay (C+D) after treatment 
with ACT-209905 (ACT, 10 µM), Compound 16 (Comp 16, 10 µM), Compound 16-ME (Comp 16-ME, 10 µM) and 
temozolomide (TMZ, 100 μM) for 48 and 72 h, administered alone and in combination. Control cells (CON) 
were treated with MeOH. (A+B) LN18 cell viability using the resazurine assay. (C+D) LN18 cell vitality using the 
Crystal-violet assay. Cell viability and vitality are shown in relation to the control (set to 100%), mean values 
and SD, n = 3, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and 
***p < 0.001 vs. control. 
 
In the GL261 cells (Figure 21A-D), the strongest cytotoxic effect was observed for the 
combined application of ACT-209905 and Compound 16-ME with a remaining viability level 
of only 12.0% after 48 hours (Figure 20A). Nearly all GL261 had died after 72 hours of 
treatment with ACT-209905 and Compound 16-ME together (Figure 21B). The application of 
10 µM ACT-209905 alone or together with TMZ did not reduce cell viability. The dual 
treatment of GL261 cells with Compound 16 or Compound 16-ME together with TMZ 
decreased the cell viability significantly to 56.4% and 72.4% after 48 hours, and to 63.5% and 
72.9% after 72 hours (Figure 20B), respectively. In contrast, incubation of GL261 cells with 





results of the cell vitality analyses (Crystal-violet staining, Figure 21C+D) showed similar data 
as for the cell viability experiments (Resazurine assay). 
In all GBM cell lines, single application of 100 µM TMZ or 10 µM Compound 16/16-ME did 
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7 2  h o u rs
 
Figure 21: GL261 GBM cell viability and vitality after dual treatment with ACT-209905, Compound 16, 
Compound 16-ME and temozolomide. Resazurine assay (A+B) and Crystal-violet assay (C+D) after treatment 
with ACT-209905 (ACT, 10 µM), Compound 16 (Comp 16, 10 µM), Compound 16-ME (Comp 16-ME, 10 µM) and 
temozolomide (TMZ, 100 μM) for 48 and 72 h, administered alone and in combination. Control cells (CON) 
were treated with MeOH. (A+B) LN18 cell viability using the resazurine assay. (C+D) LN18 cell vitality using the 
Crystal-violet assay. Cell viability and vitality are shown in relation to the control (set to 100%), mean values 
and SD, n = 3, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 0.005 and 
***p < 0.001 vs. control. 
 
5.9 Influence of ACT-209905 on caspase 3 activity in GBM cells in vitro 
Caspase 3 is a cysteine protease that plays an important role in the process of apoptotic cell 





involves the induction of apoptosis, the activity of caspase 3 was determined. The results of 
caspase 3 measurement are shown in Figure 22.  
Treatment of all GBM cells (LN18, U87MG and GL261) with 5 µM ACT-209905 for 48 hours 
did not result in significant changes of caspase 3 activity. The GBM cells treated with 20 µM 
ACT-209905 for 48 hours showed an increased activity of caspase 3 but this was not 
statistically significant. Only application of 50 µM ACT-209905 caused an elevated activity of 
caspase 3 with relative values of 0.067 AU, 0.031 AU and 0.024 AU in LN18, GL261 and 






















































Figure 22. Activity of caspase 3 in GBM cells after treatment with ACT-209905. LN18, U87MG (both human 
GBM cell lines) and GL261 (a murine GBM cell line) were treated with ACT-209905 (ACT; 5, 20 and 50 μM) for 
48 hours. Control cells were treated with the respective solvent (MeOH, 0.1%). Afterwards, caspase 3 activity 
was determined with a commercially available kit according to the manufactureers instruction. Mean values 
and SD, n = 3, One-way analysis of variance with Dunnett ś multiple comparison test, ***p < 0.001 vs. MeOH 
control. 
 
5.10 Effects of ACT-209905 on viability of LN18 GBM stem-like cells in vitro 
Glioma stem cells have emerged as a crucial player in the pathogenesis of GBM and are 
thought to be responsible for resistance to conventional therapy resulting in the rapid 
occurrence of relapses [112,113]. The cultivation of GBM neurospheres, which represent 
stem cell features, is a well-accepted method for investigation of GBM stem cell 
characteristics and behavior [114,115]. In this work, the human GBM cell line LN18 was used 





The adherent and neurosphere cells were cultured for 4 (Figure 23A) or 7 days (Figure 23B) 
followed by application of 10 µM ACT-209905 and subsequent cell viability and vitality 
analyses. 24 hours after application of 10 µM ACT-209905, the viability of LN18 adherent 
cells was not significantly diminished whereas the LN18 neurosphere cells showed a reduced 
viability of 75.2% in the 4 day-culture group (Figure 23A). Such a difference in the response 
to ACT-209905 was also found after 48 hours: the viability of adherent LN18 cells was 
diminished to 59.0% and of LN18 neurospheres to 39.2%, respectively. In contrast, 72 hours 
after application of ACT-209905 the decrease in cell viability was nearly similar for the 
adherent and neurosphere cells (4 days culture group). In sum, after treatment of LN18 
stem-like neurospheres cells (4 days in culture) with ACT-209905 for 24 h, 48 h and 72 h, the 
cell viability decreased to 75.2%, 39.2% and 6.2%, respectively. And after treatment of LN18 
stem-like neurospheres cells (7 days in culture) with ACT-209905 for 24 h, 48 h and 72 h, the 
cell viability was much more reduced to 36.6%, 4.1% and 1.1%, respectively. In the adherent 
LN18 group (serum containing media), after treatment with ACT-209905 for 24 h, 48 h and 
72 h, the cell viability decreased to 94.0%, 63.2% and 2.6% in the 4 day culture group (Figure 
23A), and to 84.1%, 59.0% and 26.7% in the 7 day culture group (Figure 23B), respectively.  
Interestingly, ACT-209905 seems to have cytotoxic effects not only in adherent glioma cells 
but also in stem-like neurosphere cells, and the cytotoxicity of ACT-209905 is even more 







Figure 23: Treatment of LN18 adherent cells and stem-like neurospheres with ACT-209905. LN18 cells were 
cultured for 4 (A) or 7 days (B) either as adherent cells or as stem-like neurospheres followed by treatment with 
ACT-209905 (10 µM) for 24 h, 48 h and 72 h. Control cells (CON) were treated with MeOH (0.1%). Cell viability 
was determined with the Resazurine assay and is shown in relation to the MeOH control (set to 100%), mean 
values and SD, n = 3, one-way analysis of variance with Dunnett ś multiple comparison test, *p < 0.05, **p < 






6   Discussion 
Glioblastoma multiforme (GBM), the most common and aggressive primary malignant brain 
tumor of adults, is notoriously fatal. Despite surgical resection and post-operative 
radiochemotherapy as the standard treatment for GBM, affected patients have a poor 
median survival of around 15 months. Therefore, an improvement of the therapeutic 
strategies is urgently needed and targeted therapies might be an alternative to the standard 
chemotherapy regimen. The bioactive lipid sphingosine-1-phosphate (S1P) has been 
implicated in various disorders such as cancer and inflammatory diseases. It is involved in 
proliferation, migration and invasion of a broad range of healthy and malignant cells [26], 
and is widely present in body fluids and cells such as red blood cells, neutrophils, and 
platelets [26]. S1P participates in various physiological functions such as immune regulation, 
hematopoietic regulation, allograft response, glucose metabolism regulation and 
inflammation [116]. S1P can act intracellularly as a second messenger or it can be moved 
outside the cell via a transporter to bind to the corresponding receptors (S1P receptors 1-5, 
S1PR1-5), and activates a series of downstream signaling pathways to produce important 
physiological functions [31]. These include cell proliferation, migration, survival, apoptosis 
and cell communication. Previous studies have shown that S1P receptors are involved in the 
regulation of proliferation, invasion, metastasis, vascular maturation and angiogenesis of 
various tumor cells, and are closely related to the occurrence and development of tumors 
[33]. Furthermore, recent studies argue for a potential role of S1P signaling in GBM growth 
and progress, too [62,69,93,117,118]. DifferentS1PR modulators have been developed such 
as fingolimod (FTY720) which is approved for treatment of multiple sclerosis. Interestingly, 
fingolimod as an S1PR1 modulator is also effective against GBM cells in vitro and in an in vivo 
mouse model, and sensitizes GBM cells to the chemotherapeutic temozolomide [119,120]. 
Whether other S1PR modulators are also active against GBM cells and whether they can be 
used clinically to provide new and effective cancer treatments is currently not known. 
Therefore, the purpose of this study was to investigate the influence of the S1PR1 modulator 
ACT-209905 (a chemical S1PR1 agonist but a functional S1PR1 antagonist) and the S1PR2 
blocker Compound 16 and Compound 16-ME on growth and migration of GBM cells in vitro. 
Thereby, the focus lay on the analysis of ACT-209905 mediated effects. In sum, the results of 





GBM cells by inhibiting the proliferation, viability and migration of GBM cells. In the 
following chapters, the results of the present work will be discussed and compared to other 
already published studies regarding the impact of S1P signaling in the pathogenesis of GBM.  
 
6.1  ACT-209905 reduces the viability of GBM cells and promote their apoptosis 
In our in vitro cell viability analyses, we found that ACT-209905 significantly reduced viability 
of the human LN18 and U87MG GBM cells as well as of the murine GL261 GBM cells. Studies 
have shown that the expression of S1PR1, S1PR2 and S1PR3 is increased in GBM tissue 
specimens compared with healthy brain tissue, but only S1PR1 and S1PR2 are significantly 
associated with patient survival [62,69]. Our previous laboratory studies showed that S1PR1 
and 2 play an important role in cell migration and invasion of LN18 GBM cells which were 
also used as an in vitro GBM cell model in the present work [62]. To understand the role of 
the S1PR1 and S1PR2 in migration and proliferation of GBM cells, we used ACT-209905 
(S1PR1 modulator, see above), Compound 16/16-ME (S1PR2 antagonists), W146 (S1PR1 
antagonist) and JTE-013 (S1PR2 antagonist) alone or in combination to treat different GBM 
cell lines in vitro. The results showed that the combined administration of the S1PR1 and 
S1PR2 antagonists has a more pronounced cytotoxic effect than single administration 
arguing for a role of both S1P receptor 1 and 2 in the growth of GBM cells. Considering the 
cell viability analyses, a direct comparison of the cytotoxic effect of ACT-209905, Compound 
16 and Compound 16-ME showed that all three substances are similar active 48 and 72 
hours after application. This also supports the assumption that both S1PR1 and S1PR2 are 
involved in the growth of GBM cells. Furthermore, we found a synergistic/additive effect of 
dual treatment of GBM cells with ACT-209905 together with the current standard 
chemotherapeutic drug temozolomide (TMZ) for 48 and 72 hours in the human LN18 and 
U87MG GBM cells but not in the murine GL261 GBM cell line. This discrepancy between 
human and murine GBM cells could be based on a different expression level of the S1P 
receptor subtype 1 (S1PR1). Our own immunoblotting results showed that the human LN18 
and U87MG cells have a 5- to 7-fold higher S1PR1 protein expression than the murine GL261 
cell line. Thus, the molecular target of ACT-209905 might be present in higher amounts in 
human GBM cell than in murine GBM cells. Unfortunately, this can t́ be examined in more 





effect, observed for co-application of ACT-209905 and temozolomide, was not seen (LN18, 
GL261) or at least not so pronounced (U87MG) for the dual application of Compound 
16/Compound 16-ME and temozolomide. Thus, inhibition of S1PR1 but not of S1PR2 
activates pathways which sensitize the GBM cells against temozolomide. 
To further analyze which pathway might be involved in the cytotoxic effect of ACT-209905 in 
GBM cells, we investigated the activation status of kinases which were previously identified 
as a part of the S1P signaling. Immunoblot analyses showed a significant 2.5-fold increase in 
the phosphorylation/activation status for both AKT1 (pAKT1) and ERK1/2 (pERK1/2) 5 and 10 
min after stimulation of LN18 cells with 2.5 μM S1P. In contrast, this increase in AKT1 and 
ERK1/2 activation by S1P was significantly diminished by application of ACT-209905. Thus, in 
LN18 cells S1PR1 seems to be responsible for the activation of AKT1 and ERK1/2 by S1P, and 
an inhibition of these kinases could be one mechanism of the cytotoxic effect of ACT-209905.  
Consistent with our results, S1P-induced Gi-coupled receptors require ERK1/2 activation to 
stimulate glioma cell proliferation and survival, and an overexpression of S1PR1 leads to 
ERK1/2 activation, which correspondingly regulates the survival and proliferation of GBM 
cells [121]. In addition, it is reported in the literature that S1PR1 and S1PR3 are responsible 
for promoting migration and survival of GBM cells, while S1PR2 attenuates cell migration 
[122]. Our previous studies have shown that S1P-stimulated LN18 cell migration can be 
completely inhibited only by blocking PI3K/AKT1 but not by inhibition of the ERK1/2 signaling 
[62]. In the present study, an increase in phosphorylation of AKT1 was seen in LN18 cells 
stimulated with S1P but not in the murine GL261 cells. Again, a various expression status of 
S1P receptor subtypes or downstream signaling molecules might be responsible for the 
different response to S1P. It is known that the PI3K/AKT1 pathway is activated by S1PR1, 
S1PR2 and S1PR3 by Gi coupling of these receptors, of which AKT1 is considered to be the 
major downstream signaling molecule of S1PR1 [124]. Thus, it seems possible that ACT-
209905 is capable of inducing autophagy, apoptosis and necrosis in GBM cells because these 
cell death processes may be reliant on the phosphatidylinositol 3-kinase/protein Kinase B 
(PI3K/AKT1) signaling pathway. Consistent with this, ACT-209905 caused the activation of 






6.2  ACT-209905 inhibits the migration of GBM cells 
Using two different approaches (wound healing scratch assay, Boyden chamber invasion 
assay), the data of the present work demonstrate that ACT-209905 inhibits the migration of 
GBM cells., This might be primarily caused through the inhibition of S1PR1 by ACT-209905, 
since it is known that the activation of S1PR1 leads to the activation of ERK1/2, which in turn 
results in the migration of GBM cells [125,126]. ERK1/2 and AKT1 activation was inhibited by 
ACT-209905 in LN18 GBM cells which can both be activated by stimulation of S1PR1 by S1P 
[127]. Thus, inhibition of both the PI3K/AKT1 and the ERK1/2 signaling pathway by ACT-
209905 may be responsible for the decreased migration of GBM cells after application of 
ACT-209905. 
The PI3K/AKT1 signaling pathway is important for intracellular regulation of cell survival or 
death. Moreover, the PI3K/AKT1 is pathway is closely related to cell invasion and metastasis. 
A recent study of our group has shown that inhibition of PI3K/AKT1 signaling by LY294002 
completely inhibited S1P stimulated LN18 cell migration but not inhibition of ERK1/2 by 
PD98059 [62]. The PI3K/AKT1 pathway is known to be activated by S1PR1, S1PR2 and S1PR3 
via Gi-coupling of these receptors [118]. For S1PR1 and S1PR3 a PI3K/AKT1-dependent 
stimulation of cell migration is described whereas S1PR2 uses this signaling cascade only as a 
side trail while Rho signaling as the main pathway may negatively regulate cell migration 
[118]. Thus, at least in LN18 GBM cells, the PI3K/AKT1 pathway may be primarily responsible 
for migration after stimulation with S1P which is in turn reduced through the inhibition of 
the S1PR1-PI3K/AKT1 signaling cascade by ACT-209905. Studies have found that in mouse 
glioma cells, the use of PI3K inhibitors cause concentration- and time-dependent inhibition 
of tumor cell invasion, and this invasion inhibition is closely related to the phosphorylation 
level of AKT1 [62,124]. After application of the inhibitors, the expression levels of MMP-2 
and MMP-9 in the tumor cells was significantly decreased. This suggests that the PI3K/AKT1 
signaling pathway is also involved in the regulation of MMPs which in turn modifies the 
invasive capacity of tumor cells [128]. It was also found that FTY720 (fingolimod), another 
S1PR1 modulator, significantly inhibited the phosphorylation levels of AKT1, mTOR and 
p70S6K in the human U251MG and U87MG cell lines without significant effects on total AKT, 
mTOR and p70S6K [120]. In addition, PI3K kinase inhibitor LY294002 down-regulated the 





indicating that the PI3K/AKT1 signaling pathway and FTY720-mediated inhibition of GBM cell 
invasion are closely related to each other [120]. Overall, our data argue for a participation of 
S1PR1 signaling in proliferation and migration of GBM cells, at least in the human GBM cell 
lines LN18 and U87MG and the mouse GBM cell line GL261. Whether this is also true for 
primary GBM cells, freshly isolated from tumor tissue, has to be analyzed in further studies. 
 
6.3 ACT-209905 reduces the viability of GBM stem cells, and modifies their CD133 and 
Nestin expression 
The theory of cancer stem cells makes us realize that malignant tumors are formed by the 
ability of stem cells to undergo abnormal self-renewal after multiple mutations, and further 
proliferate and differentiate [129]. According to the theory of cancer stem cells, only a very 
small number of cells in the tumor have the potential of unlimited proliferation, self-renewal 
and multi-directional differentiation. They are the root cause of tumorigenesis, metastasis 
and recurrence, and are the main targets of tumor treatment in the future [130]. 
Unfortunately, the current medical treatment strategies based on chemotherapy and 
radiotherapy only kills the tumor cells after the differentiation of cancer stem cells, so that 
the number of tumor cells is reduced, and the tumor shrinkage can be observed, but the 
tumor stem cells have no obvious effect [131-140], so the patient is difficult to get long-term 
survival. Studies have shown that brain tumor stem cells (BTSCs) are insensitive to 
chemotherapy and radiotherapy. BTSCs can proliferate to form new tumors due to their 
ability to self-renew, which is why there is recurrence after the surgical removal of tumors. 
Therefore, targeted treatment of BTSCs holds the key to prevent tumor recurrence after 
surgery and (radio)chemotherapy [130]. GBM stem cells are a popular field of research for 
studying the efficiency and molecular pathways of anti-GBM drugs because they are 
generally not sensitive to the clinical application of modern drugs, and radiotherapy is 
almost ineffective. CD133 is a transmembrane protein with a molecular weight of 120 kDa, 
which initially thought to be a marker of hematopoietic stem cells, but it was later found 
that CD133 mRNA transcripts were also detected in normal non-lymphoid hematopoietic 
tissues [141]. Since Singh et al. [102] isolated CD133-positive cells with tumor stem cell 
characteristics from the tumor tissues in 2003, CD133 has been used for the identification of 





gliomas the proportion of CD133-positive cells is increased with the grade of tumor, and 
tumors with a high amount of CD133-positive cells have a high malignancy, short patients 
survival time after surgery, and a high recurrence rate [103]. A further stem cell marker is the 
type VI intermediate filament protein Nestin which was discovered in 1985 to be expressed 
in the spinal canal neural stem cells of embryonic rat. Since Nestin expression is high in 
neural precursor cells, it was always considered to be a marker of neural precursor cell [105]. 
With the development of glioma stem cell theory and the studies of related markers, Nestin 
has also been used in the identification of cancer stem cells in recent years, and has been 
recognized by many scholars as a marker of brain cancer stem cells [142-144]. 
Our immunoblot data showed that Nestin and CD133 were more highly expressed in the 
ACT-209905 treated LN18 cells than the S1P treated cells (Figure 10). In contrast, in the 
murine GL261 GBM cells, ACT-209905 did not cause a significant increase in CD133 and 
Nestin expression whereas S1P significantly enhanced the protein level of CD133 and Nestin 
in these cells (Figure 11). Of note, a various S1PR1 expression may be responsible for such 
cell type dependent differences. Such a cell type dependent effect was also seen for 
Compound 16: whereas the S1PR2 inhibitor did not cause an increase of CD133 or Nestin in 
the human LN18 cells, a significant up-regulation of both stem cell marker was observed in 
the mouse GL261 cells. Nevertheless, it does not mean that ACT-209905 or Compound 16 
have no therapeutic effect on GBM stem cells while ACT-209905 acts as an structural 
activator of S1PR1 but is an functional S1PR1 antagonist. The reason may be that CD133 has 
limitations as a glioma stem cell marker. Comparing the tumorigenic ability of CD133 positive 
and negative cells, it was found that CD133 positive cells have strong tumorigenic ability, 
while negative cells have no tumorigenic ability [141,145]. For this reason, CD133 was 
considered to be the most important marker for brain tumor stem cells. Since then, CD133 
has been widely used as a molecular marker for the isolation and purification of brain tumor 
stem cells, and plays an important role in the research of brain tumor stem cells. CD133 
expression is not detected in most glioma cell lines and in some fresh malignant glioma 
tissues [146,147]. Notably, in the present study, CD133 protein was detected by 
immunoblotting in the human LN18 GBM cell line as well as in the murine GL251 GBM cell 
line which is accordance with our previous work and the studies from Hossain and 





chemoresistance as well as GBM survival [101,134,150]. Interestingly, recent studies depict 
that also CD133-negative glioma stem-like cells exist [147,151], and that the expression of 
CD133 may reflect the environmental conditions and stress responses. Further, several 
models have shown the stem cell capacity of CD133-negative GBM cells [152-155]. It is 
assumed that the presence of various CD133 phenotypes in glioma stem cells may be due to 
the differences in their originally differentiated cells [156,157]. Of note, it is believed that a 
phenotypic shift from CD133 negative to CD133 positive cells under hypoxic conditions exist, 
while CD133 postive cells return to CD133 negative cells under normal oxygen conditions 
[153]. Joo et al. [146] found that four of six resected GBM tissues had CD133 positive cells, 
and two of them contained CD133 negative cells. After inoculation into NOD-SCID (non-
obese diabetes in severe combined immunodeficiency) mice, both CD133 positive and 
CD133 negative cells caused a glioblastoma, and the CD133 negative cells showed greater 
invasiveness and angiogenic ability. Thus, an up-regulation of CD133, as seen in our study, by 
both S1P and the functional S1PR1 receptor antagonist ACT-209905 does not necessarily 
result in a higher aggressivenes of the tumor cells. Interestingly, the S1PR2 blocker 
Compound 16/16-ME did not cause an increase in CD133 or Nestin expression in human 
LN18 GBM cells arguing for a S1PR1 subtype dependent effect.  And in conclusion, the 
results suggest the complexity of CD133 as a marker for glioma tumor stem cells. From the 
functional aspect, the physiological function of the CD133 protein has not yet been 
elucidated. 
Besides CD133, the intermediate filament protein Nestin was increased after application of 
ACT-209905 in human LN18 GBM cells. Nestin is a molecular marker that is specifically 
expressed on neuroepithelial stem cells, and it is also one of the most commonly recognized 
markers of BTSC in addition to CD133. Nestin expression is closely related to the "stem cell" 
phenotype and is a skeleton protein expressed in progenitor cells and neural stem cells. 
Cattaneo et al. [158] found that the expression of differentiation markers such as GFAP (Glial 
fibrillary acidic protein) in neural stem cells increased while the expression of Nestin 
decreased. Tohyama and colleagues [159] showed that Nestin expression was positive in 
multiple types of brain tumors. Studies from Rutka et al. [143] demonstrate that Nestin 
positive brain glioma cells have some features in common with neural stem cells. Compared 





Kleeberger et al. [160] found that Nestin expression can promote tumor migration and 
metastasis. In line with these observations, a prognostic influence of Nestin expression in 
GBM was shown [148,150,161]. But Nestin expression is not sufficient to indicate that 
Nestin-expressing cells are indeed cancer stem cells. It is one typical marker of tumor stem 
cell but not the only one. To clarify the meaning of the up-regulation of both Nestin and 
CD133 by ACT-209905 in human LN18 GBM cells further detailed studies are urgently 
needed. At this point of work, a conclusion cannot be drawn, but although ACT-209905 
induced a higher expression of Nestin and CD133 in GBM cells, ACT-209905 still had the 
capacity to inhibit the proliferation, migration and invasion of LN18, U87MG and GL261 GBM 
cells in the present study.  
Of note, the cell viability analyses of the present work show that the application of ACT-
209905 was effective against adherent GBM cells whereas the standard chemotherapeutic 
temozolomide (100 µM) had only minor cytotoxic effects. Studies have shown that the 
maximal temozolomide concentration in serum is about 75 µM [162], thus the 
temozolomide concentration chosen in the present work is comparable to the in vivo 
situation.  
Interestingly, the cytotoxic effects of ACT-209905 were more pronounced in the LN18 
neurosphere cells which are described to have stem cell features [101,163]. We hypothesize 
that ACT-209905 has a similar effect as the S1PR1 modulator FTY720 (fingolimod), because 
FTY720 also causes apoptosis of glioma cells and has cytotoxic effects against glioma stem 
cells, too [117,119]. FTY720 rapidly inactivates the ERK1/2 kinase activity of BTSCs and 
increases the expression of cleaved Caspase 9, Caspase 7 and Caspase 3, resulting in the 
death of brain tumor stem cells [117]. In the present work, the S1PR1 modulator ACT-
209905 also diminished the activity of ERK1/2 induced by S1P in LN18 GBM cells but has no 
effect on the basal ERK1/2 activity as described for FTY720. In concordance with FTY720, 
caspase 3 activity was also increased by ACT-209905 leading to cell death of GBM cells in our 
study. Further, FTY720 is known to inhibit the activation of the PI3K/AKT1 pathway leading 
to a reduced migration of GBM cells [120]. A related effect was observed in the present work 
for ACT-209905 which caused a decrease in the S1P-induced activation of AKT1 combined 
with a diminished migration of LN18 cells but had only a slight influence on the basal AKT1 





mice, similar to the original tumors [140], and are therefore considered to be important cells 
for the targeted treatment of GBM. When human GBM-derived stem cells, which formed 
neurosphere-like cells, are injected into the brain of nude mice, new tumors develop 
representing an accurate and reliable pathological model of GBM [164]. Therefore, we also 
used the neurosphere model to investigate the cytotoxic efficiency of ACT-209905 in GBM 
cells. As described above, the viability of LN18 neurosphere cells was stronger affected than 
their adherent counterparts arguing for a potential therapeutic effect of ACT-209905 against 
glioma stem cells. In a next step to preclinically evaluate ACT-209905 as treatment option, 
GL261 GBM cells and GL261-derived GBM stem cells should be injected into the brain of 
mice followed by ACT-209905 treatment as performed for FTY720 by Estrada-Bernal and 
colleagues [117]. If the results show that ACT-209905 is effective in treating GBM in vivo, and 
can significantly prolong the survival period and reduce tumor growth (consistent with our in 
vitro studies) this would validate the anti-GBM effect of ACT-209905 much more. Although 
TMZ is still the current mainstream anti-tumor drug for therapy of GBM, a combination of 
ACT-209905 and TMZ may then show better therapeutic effects. This question should 
therefore be urgently addressed. 
 
6.4 ACT-209905 might have various effects in different source GBM cells 
Our in vitro results show some differences in the effects of ACT-209905 in the human LN18 
and the mouse GL261 cell line. Despite a similar cytotoxicity of ACT-209905 in both cell lines, 
the migration was somewhat more inhibited in GL261 cells and the induction of caspase 3 
activity as apoptosis marker was more pronounced in LN18 GBM cells. A strong difference 
was found for the AKT1 and ERK1/2 activity influenced by ACT-209905. Whereas in LN18 
cells, ACT-209905 caused a decrease in S1P-induced activation of both kinases, in GL261 cells 
S1P-induced activation of ERK1/2 was not diminished by ACT-209905. Additionally, in murine 
GL261 GBM cells no activation of AKT1 was observed by S1P alone but curiously by co-
application S1P and ACT-209905 together. Compared with the S1PR1 modulator FTY720, 
which also inhibits activation of both AKT1 and ERK1/2 in human GBM cells, ACT-209905 has 
similar effects in the human LN18 GBM cells [117,120]. A further interesting difference was 
observed for expression of the stem cell marker CD133 and Nestin. In the human LN18 GBM 





in the mouse GL261 cells (Figure 10 and 11). The potential consequences were already 
discussed in chapter 6.3.  
This difference in the response of GBM cells to ACT-209905 could be based on different 
genetic backgrounds, pathological types, differentiation states, gene mutation profiles and 
transcriptomes, proteome expression profiles, etc., reflecting the high complexity and 
diversity of GBM cells [165-170]. Furthermore, an intra-tumoral heterogeneity of GBM is 
shown by how the cellular composition of each tumor is more heterogeneous than 
previously predicted, resulting in a diversification of cells within the tumor. This is due to the 
different cells in the tumor exhibiting various mutations and expressing genes in different 
ways. This diversity may lead to tumor resistance and recurrence. To map out these 
differences, Patel et al. [171] isolated glioblastoma tissue from five patients and made a 
single cell suspension for 430 isolated tumor single cells. Afterwards, RNA-sequencing (RNA-
Seq) technology for transcriptome analysis successfully obtained a more detailed map of 
tumor cell composition. Their results showed that each glioblastoma contains cells from 
multiple cancer subtypes, and the distribution of these cells between tumors differs. Further 
clustering occurs according to their similarity, and although each patient's cell similarity was 
found to be higher (than the individual), there are still some differences. The cancer cells in 
these tumors survived in various states. Some of them have stem cell features with the 
ability to self-renew, which may play a role in tumor recurrence after treatment. More 
mature, differentiated cancer cells constitute the majority of the tumor cell population. It is 
this tumor heterogeneity that causes great difficulties in the treatment of GBM, and is one of 
the most important scientific issues in the research field of GBM development mechanics. 
Matching with this, the GBM cell lines analyzed in the present work had different expression 
levels of the five S1P receptor subtypes (Figure 1). For example, the human LN18 cells, used 
in this study, showed a higher expression of the S1PR1, S1PR2, S1PR4 and S1PR5 than the 
murine GBM cells whereas the S1PR3 was very similar between both cell lines. GBM cells of 
different species may have different biological characteristics and this could be responsible 
for the inconsistency of some experimental results as described above. The opposite results 
obtained from human LN18 and murine GL261 GBM cells may be possibly caused of 
differences in biological characteristics due to their species. This suggests that when 





consider these potential differences in experimental results in light of their biological 
characteristics and with regard to a generalisation and transferring results from one cell line 
to another or even to primary cells. We have to keep in mind that there are multiple 
subtypes of GBM with heterogeneous genetic/genomic/epigenetic features leading to 
various methods to classify tumors according to the key molecular events that drive the 
most aggressive cellular components so that targeted therapies can be developed for 
individual subtypes [172]. Further, depending on the different GBM cell types within the 
same tumor, we may need to treat malignant tumors based on all the cell subtypes 
contained in each tumor rather than just the most common subtype [173-175]. 
 
6.5 Outlook 
Taken together, our results indicate that ACT-209905, a modulator of S1PR1 function, 
inhibits GBM growth/proliferation, invasion and migration, and also induces apoptosis in 
GBM cells. In addition, ACT-209905 is effective against GBM stem-like cells demonstrated by 
the neurospheres assays performed in this study. Therefore, further systematic studies of 
the anti-tumoral mechanisms of S1PR1 modulators, such as ACT-209905 or FTY720, may 
help to develop new strategies to treat patients suffering from GBM. For example, it is 
necessary to evaluate the specific pathways involved in the cytotoxic effect of ACT-209905 
for better understanding of both the tumor pathogenesis and the molecular mode of action 
of ACT-209905. Additionally, primary GBM cells freshly isolated from tumors should be 
treated with ACT-209905, too, to examine whether ACT-209905 is also effective in these 
cells. The use of astrocytic and neural cell models could further clarify if healthy astrocytes 
and neurons are also killed by ACT-209905 to assess potential adverse effects. Furthermore, 
it is particularly important to pre-clinically evaluate the efficiency of ACT-209905 in a suitable 
animal model to check whether blocking of S1PR1 indeed reduces the growth of GBM in vivo 
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